Study Title: VE303 for Treatment of Hepatic Encephalopathy (HE)
PI: Patricia Pringle Bloom, MD
NCT: [STUDY_ID_REMOVED]
Document Approval Date: 2/16/2023
A Randomized Controlled Trial of VE303 to Treat Hepatic  
Encephalopathy  
VE303  for Treatment  of HE 
Protocol  Number:  HUM00194437  
IND Number:  IND27324  
National  Clinical  Trial  (NCT)  Identified Number:  [STUDY_ID_REMOVED]   
Principal  Investigator:  Patricia Pringle  Bloom  MD 
IND Holder: Patricia Pringle Bloom MD  
Funded by: ACG Junior Faculty Development Award  
And AASLD  Advanced  Hepatology  Fellowship  Award  
Vedanta  Biosciences  Inc 
University of Michigan  
Version Number:  V6 
 November 14, 2022  
NIH-FDA Clinical  Trial  Protocol  Template  – v1.0 7  Apr 2017  ii  Table  of Contents  
STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1 PROTOCOL  SUMMARY  ................................ ................................ ................................ ...............................  1 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  1 
1.2 Schema  ................................ ................................ ................................ ................................ .................  2 
1.3 Schedule  of Activities  (SoA)  ................................ ................................ ................................ ...............  3 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  4 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 4 
2.2 Background ................................ ................................ ................................ ................................ ...........  4 
2.3 Risk/Benefit  Assessment  ................................ ................................ ................................ ....................  5 
2.3.1  Known  Potential  Risks  ................................ ................................ ................................ ..... 5 
2.3.2  Known  Potential  Benefits  ................................ ................................ ................................  6 
2.3.3  Assessment  of Potential  Risks and  Benefits  ................................ ................................  6 
3 OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ................................ ................  6 
4 STUDY  DESIGN  ................................ ................................ ................................ ................................ .............  8 
4.1 Overall  Design  ................................ ................................ ................................ ................................ ...... 8 
4.2 Scientific  Rationale  for Study Design  ................................ ................................ ................................  9 
4.3 Justification for  Dose  ................................ ................................ ................................ ...........................  9 
4.4 End of Study Definition  ................................ ................................ ................................ .....................  10 
5 STUDY  POPULATION  ................................ ................................ ................................ ................................  10 
5.1 Inclusion  Criteria  ................................ ................................ ................................ ................................  10 
5.2 Exclusion  Criteria  ................................ ................................ ................................ ...............................  10 
5.3 Lifestyle  Considerations  ................................ ................................ ................................ ....................  11 
5.4 Screen  Failures  ................................ ................................ ................................ ................................ .. 11 
5.5 Strategies for  Recruitment  and Retention  ................................ ................................ ......................  12 
6 STUDY  INTERVENTION  ................................ ................................ ................................ ............................  12 
6.1 Study  Intervention(s)  Administration  ................................ ................................ ...............................  12 
6.1.1  Study  Intervention  Description  ................................ ................................ .....................  12 
6.1.2  Dosing  and Administration  ................................ ................................ ............................  12 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  13 
6.2.1  Acquisition  and accountability  ................................ ................................ ......................  13 
6.2.2  Formulation,  Appearance,  Packaging,  and Labeling  ................................ ................  13 
6.2.3  Product Storage  and Stability  ................................ ................................ .......................  13 
6.2.4  Preparation  ................................ ................................ ................................ ......................  14 
6.3 Measures  to Minimize  Bias:  Randomization  and Blinding  ................................ ...........................  14 
6.4 Study  Intervention  Compliance  ................................ ................................ ................................ ........  14 
6.5 Concomitant  Therapy  ................................ ................................ ................................ ........................  15 
6.5.1  Rescue  Medicine  ................................ ................................ ................................ ............  15 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ................................ ....................  16 
7.1 Discontinuation  of Study  Intervention  ................................ ................................ .............................  16 
7.2 Participant Discontinuation/Withdrawal  from the Study  ................................ ...............................  17 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  17 
8 STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ................................ ......................  18 
8.1 Efficacy  Assessments  ................................ ................................ ................................ .......................  18 
8.2 Safety  and Other  Assessments  ................................ ................................ ................................ ....... 19 
8.3 Adverse  Events  and Serious  Adverse  Events  ................................ ................................ ...............  20 
NIH-FDA Clinical  Trial  Protocol  Template  – v1.0 7  Apr 2017  iii  8.3.1  Definition  of Adverse Events  (AE)  ................................ ................................ ...............  20 
8.3.2  Definition  of Serious  Adverse  Events  (SAE)  ................................ ..............................  21 
8.3.3  Classification  of an Adverse  Event  ................................ ................................ ..............  21 
8.3.4  Time  Period  and Frequency  for Event  Assessment  and Follow -Up .......................  22 
8.3.5  Adverse  Event  Reporting  ................................ ................................ ..............................  23 
8.3.6  Serious  Adverse Event  Reporting  ................................ ................................ ...............  23 
8.3.7  Reporting  Events  to Participants  ................................ ................................ .................  23 
8.3.8  Events  of Special Interest  ................................ ................................ .............................  24 
8.3.9  Reporting  of Pregnancy  ................................ ................................ ................................  24 
8.4 Unanticipated  Problems  ................................ ................................ ................................ ....................  24 
8.4.1  Definition  of Unanticipated Problems  (UP)  ................................ ................................ . 24 
8.4.2  Unanticipated  Problem  Reporting  ................................ ................................ ................  24 
8.4.3  Reporting  Unanticipated Problems  to Participants  ................................ ...................  25 
9 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ...........  25 
9.1 Statistical  Hypotheses  ................................ ................................ ................................ .......................  25 
9.2 Sample  Size Determination  ................................ ................................ ................................ ..............  26 
9.3 Populations  for Analyses  ................................ ................................ ................................ ..................  26 
9.4 Statistical  Analyses ................................ ................................ ................................ ............................  26 
9.4.1  General  Approach  ................................ ................................ ................................ ..........  26 
9.4.2  Analysis  of the Primary  Efficacy  Endpoint(s)  ................................ .............................  26 
9.4.3  Analysis  of the Secondary  Endpoint(s)  ................................ ................................ ....... 26 
9.4.4  Safety  Analyses  ................................ ................................ ................................ ..............  27 
9.4.5  Baseline  Descriptive Statistics  ................................ ................................ .....................  27 
9.4.6  Planned  Interim  Analyses  ................................ ................................ .............................  27 
9.4.7  Sub-Group  Analyses  ................................ ................................ ................................ ..... 27 
9.4.8  Tabulation  of Individual participant  Data  ................................ ................................ .... 27 
9.4.9  Exploratory  Analyses  ................................ ................................ ................................ ..... 27 
10 SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS ...............................  27 
10.1 Regulatory,  Ethical,  and Study  Oversight  Considerations  ................................ ...........................  27 
10.1.1  Informed  Consent  Process  ................................ ................................ ...........................  27 
10.1.2  Study  Discontinuation and Closure  ................................ ................................ .............  28 
10.1.3  Confidentiality  and Privacy  ................................ ................................ ...........................  29 
10.1.4  Future  Use of  Stored Specimens  and Data  ................................ ...............................  29 
10.1.5  Key Roles  and Study  Governance  ................................ ................................ ..............  30 
10.1.6  Safety  Oversight  ................................ ................................ ................................ .............  30 
10.1.7  Clinical  Monitoring  ................................ ................................ ................................ ..........  30 
10.1.8  Quality  Assurance and  Quality  Control  ................................ ................................ ....... 31 
10.1.9  Data  Handling and Record Keeping  ................................ ................................ ............  31 
10.1.10  Protocol  Deviations  ................................ ................................ ................................ ........  32 
10.1.11  Publication  and Data Sharing Policy  ................................ ................................ ...........  32 
10.1.12  Conflict  of Interest  Policy  ................................ ................................ ..............................  32 
10.2 Additional  Considerations  ................................ ................................ ................................ .................  32 
10.3 Abbreviations  ................................ ................................ ................................ ................................ ...... 33 
10.4 Protocol  Amendment  History  ................................ ................................ ................................ ...........  35 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  36 
12 APPENDIX  1 ................................ ................................ ................................ ................................ .................  38 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
1  
   STATEMENT  OF COMPLIANCE   
 
The trial will be carried  out in accordance  with  International  Conference  on Harmonization  Good  
Clinical  Practice  (ICH  GCP)  and the following:  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR  
Part 46, 21  CFR Part 50, 21  CFR Part 56, 21  CFR Part 312, and/or  21 CFR Part 812)  
 
National  Institutes  of Health  (NIH) -funded  investigators  and clinical  trial site staff  who  are 
responsible for the conduct, management, or oversight of NIH -funded clinical trials have  
completed  Human  Subjects  Protection  and ICH GCP Training.  
 
The protocol,  informed  consent  form(s),  recruitment  materials,  and all participant  materials  will 
be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both  
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by the IRB before the changes are  
implemented to the study.  In addition, all changes to the consent form will be IRB -approved; a  
determination will be made regarding whether a new consent needs to be obtained from  
participants  who  provided  consent,  using  a previously  approved  consent  form.  
 
 
 
 
Title:  
A Randomized  Controlled  Trial  of VE303  to Treat  Hepatic  Encephalopathy  
Study  Description:  This is a randomized controlled trial of VE303 in patients with a history of  
overt hepatic encephalopathy (OHE). VE303 is a live biotherapeutic  
product comprising 8 nonpathogenic commensal strains of Clostridia. The  
duration of intervention is approximately 18 days and post -intervention  
follow -up is 6 months. This is the first trial to use VE303 for treating this  
condition. Our hypothesis is that VE303 will reduce the number of  
recurrent OHE episodes. A detailed schematic describing all v isits and a  
schedule of assessments are in the Schema and Schedule of Activities,  
Sections  1.2 and 1.3, respectively.  
Objectives:  Primary  Objectives:  
Evaluate  the safety  and tolerability  of VE303  in patients  with  cirrhosis.  
Determine if VE303 improves cognitive function as assessed by  
psychometric  HE score  (PHES).  
 
Secondary  Objectives:  
Determine  if VE303  reduces  hospitalizations  for OHE  in the 6 months  after  
administration.  
Determine if VE303 changes the microbiome composition in cirrhosis,  
including  colonization  of VE303  strains.  
Determine if VE303 changes serum and stool biomarkers including short - 
chain  fatty  acids, bile  acids, ammonia,  and inflammatory  markers.  
1.1 SYNOPSIS  
1 PROTOCOL  SUMMARY  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
2  
  
Endpoints:  Primary Safety Endpoint: Number of serious adverse events up to Week 6  
(4 weeks  post  VE303).  
 
Primary Efficacy Endpoint: Change in PHES as a measure of cognitive  
function  from  pre-vancomycin  to Week  6 (4 weeks  after  VE303).  
 
Secondary  Endpoints:  
- Number  of hospitalizations  for OHE up  to Week  26. 
- Adverse  events  up to Week  26 
- Change  in patient  reported  outcomes  from  pre-vancomycin  to 
Week  26 
- Time  to overt  HE 
- Change  in microbiome  composition  from  pre-vancomycin  to Week  
26 
- Change  in serum  and stool  biomarkers  from  pre-vancomycin  to 
Week  26 
- PHES  from  pre-vancomycin  to Week  26 
- Stroop  test at Week  4 and Week  26 
Study  Population:  The study  sample  will include  18 adult  patients  (aged  18-75 years  old) with  
a history  of cirrhosis  and at least  one prior  episode  of overt  HE (OHE).  
Phase:  Phase  2a trial 
Description of  
Sites/Facilities  Enrolling  
Participants:  
Description of Study  
Intervention:  This is a single -center blinded trial, enrolling only at the University of  
Michigan.  
Patients  with  cirrhosis  and a history  of OHE.  
All enrolled  subjects  will receive  5 days  of oral vancomycin  125 mg QID.  
Starting the last day of oral vancomycin (Day 1), subjects will receive 5  
capsules of VE303 or placebo daily for 14 days. VE303 and placebo  
capsules  will be  provided  by Vedanta.  
Study  Duration:  18 months  
Participant  Duration:  7 months  
 
 
 
1.2 SCHEMA  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
3  
  
 
1.3 SCHEDULE  OF ACTIVITIES  (SOA)  
 Pre- 
Screen  Screening  Treatment  Assessments  
(O = Office,  V = Virtual)  Post -Treatment  Assessments  
 
 
Day -40 to  -4 
 
Day -25 to  -4 
(0) 
 
Visit  1, Day -4 
(V) 
 
Visit  2, Day 1 
(O) 
 
Visit  3, Day 8 
± 2 days (V)  
 
Visit  4, Day 
14 (O) 
 
Visit  5, Week  
4 ± 2 days  (V) 
 
Visit  6, Week  
6 ± 2 days  (O) 
Visit  7-9, 
(Weeks  10, 
14, 18 ± 2 
weeks)  (V) 
 
Visit  10, week  
26 ± 2 weeks  
(O) 
Clinical  Assessments  
Informed  
Consent   x         
Determine  
Eligibility  (in part)  x         
Randomize     x       
Demographics   x         
Medical  History  x x         
Symptom  
assessment, ER  
and hospital  
admissions   x x x x x x x x x 
Full Physical  
Exam   x  x  x  x  x 
Height   x         
Weight   x  x  x  x  x 
Vital  Signs1  x  x  x  x  x 
Educational  
Session   x         
Medication  List x x x x x x x x x x 
Intervention  
adherence  
assessment2     x x     
Lactulose/  
Rifaximin  
Compliance  x x x x x x x x x x 
Speech  
assessment   x  x  x  x  x 
PROMIS  QOL  
test 
10 min  x  x  x  x  x 
Bristol  Stool  
Scale     x  x  x  x 
PHES  
15-20 min  x  x  x  x  x 
Stroop  Test 
10-20 min  x  x  x  x  x 
Collect  solicited  
adverse  events     x x x x x   
Collect  
unsolicited  AEs   x x* x x x x x x 
Complete case 
report  forms   x x x x x x x x x 
Laboratory Assessments  
CBC  + platelet   x  x  x  x  x 
Basic metabolic  
panel   x  x  x  x  x 
Liver  panel   x  x  x  x  x 
PT/INR   x  x  x  x  x 
Amylase  and 
lipase  level     x  x  x   
Urine  
Pregnancy3  x         
Venous  
Ammonia   x  x  x  x  x 
C.difficile  test4  x         
 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
4  
  
Stool  
Sequencing  
Sample   x  x  x x x  x 
Stool  ammonia   x  x  x  x  x 
Stool rifaximin  
level     x  x  x   
Stool vanc  level     x       
Serum  
inflammatory  
biomarkers,  
LPS,  SCFA   x  x  x  x  x 
Stool  bile acids   x  x  x  x  x 
Stool  SCFAs   x  x  x  x  x 
Archive  Stool   x  x  x  x  x 
Archive  Serum   x  x  x  x  x 
Intervention  
Vancomycin    For 5 days        
VE303  or 
placebo     For 14 days x x     
1 We will collect  temperature,  heart  rate, and blood  pressure  
2 For virtual  visit, ask  subject  to show  # of pills remaining  in study  pill bottle.  For in person  day 14 visit,  count  remaining  pills in study  pill bottle  
3 Women  of childbearing  potential  
4 C.difficile  testing  is with EIA test for CDI antigen  and toxin  A and B. If EIA test is inconclusive,  the PCR  will be run. 
*For the time period between starting vancomycin and VE303 or placebo, subjects are instructed to contact the study team if t hey experience any adverse  
effects  with taking vancomycin.  Subjects  will be asked about  adverse events  on day  1. 
**If a patient’s  planned  vancomycin  start date is over 14 days after screening,  an additional  blood  draw  for a basic  metabolic  panel  will be performed  on 
Day -6 to check  creatinine.  Those  with a serum  creatinine  1.5 – 2.0 mg/dL  at screening  or on Day -6 will have  an additional  blood  draw  for basic  metabolic  
panel  obtained on Day  -2 to check creatinine.  
 
 
  2.1   STUDY  RATIONALE   
Hepatic encephalopathy (HE) is a complication of cirrhosis characterized by impaired cognition and  
abnormal psychomotor function. Up to 40% of patients with cirrhosis will develop HE, which leads to  
impaired quality of life, frequent hospital admissions, falls, and increased mortality.(1) First line HE  
treatment, lactulose, has limited efficacy with adverse effects that may include diarrhea, electrolyte  
disarray,  dehydration,  and patient  discomfort.(2)  Rifaximin,  a second  line treatment,  is well tolerated  but 
not accessible to many patients because of its costs and frequent insurance denial. The combination of  
lactulose  and rifaximin  is not completely  effective  at preventing  recurrent  HE episodes,(3)  and both  must  
be administered long -term after the onset of HE to prevent recurrence. More effective, less toxic and  
preferably finite therapies are needed to prevent overt HE episodes and treat minimal or subclinical HE  
that persists after overt HE (OHE) episodes. Manipulating the intestinal microbiome has been proposed  
to treat  HE because  of prior  work  demonstrating  that HE develops  through  multiple  mechanisms  including  
from intestinal microbial products traversing the intestinal mucosa, crossing the blood -brain barrier, and  
affecting  brain  function.  Indeed,  lactulose  and rifaximin  as treatment  of HE work  in part through  
manipulation  of the intestinal microbiome.  
We are performing a randomized, placebo -controlled, double -blind trial of VE303 to prevent recurrent  
OHE and improve cognition in patients with cirrhosis and a history of OHE. VE303 is a live biotherapeutic  
product  composed  of 8 nonpathogenic,  nontoxigenic  strains  of Clostridia  developed  to prevent  C. difficile  
infection,  with  characteristics  that make  it a promising  treatment  for HE. 
 
  2.2 BACKGROUND   
Currently available HE treatments are flawed. There are two available FDA -approved therapies: lactulose  
and rifaximin.  Lactulose  frequently  leads  to side effects,  including  diarrhea,  bloating,  electrolyte  disarray,  
2 INTRODUCTION  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
5  
  
and dehydration.  Rifaximin,  while  causing  fewer  side effects,  is costly  and not covered  by many  insurance  
programs,  thus  limiting  its accessibility  to many  patients.  Finally,  both  these  therapies  are not perfect  and 
many  patients  develop  overt  HE or  experience  ongoing  mild  HE symptoms  despite  treatment.  
 
Manipulating  the intestinal  microbiome  has been  proposed  to treat  HE because  of prior  work  
demonstrating  that HE develops  at least  in part from  intestinal  microbial  products  traversing  the intestinal  
mucosa,  crossing  the blood -brain  barrier,  and affecting  brain  function.(4,  5) Microbiome -directed  therapy  
could plausibly treat  HE for several reasons:  first,  lactulose and  rifaximin,  current  standard -of-care  
treatments for HE, improve cirrhotic microbiome dysbiosis and function.(6 -8) Second, replacing the gut  
microbiome with bacteria lacking urease in a mouse model led to reduced ammonia production and  
improved  neurobehavioral  function.(9)  Third,  a meta -analysis  found  that probiotics  given  to patients  with  
HE decreased  plasma  ammonia.(10)  Fourth,  two trials  of fecal  microbiota  transplant  (FMT)  have  
demonstrated  improved  cognition  in patients  with  a history  of OHE.(11, 12)  
 
Several  plausible  mechanisms  link the intestinal  microbiome  to HE: 1) Intestinal  dysbiosis  in cirrhosis  leads  
to increased  ammonia  production  and therefore  increased  risk of HE. Evidence  for this mechanism  comes  
from cirrhotic patients with minimal HE who were found to have a significant linear correlation between  
intestinal  concentrations  of urease -containing  Streptococcus  salivarius  and higher  serum  levels  of 
ammonia.(13) Invasion of the distal intestine with oral commensals in cirrhosis perhaps explains the  
elevated  abundance  of these  ammonia -producing  Streptococcal  species  in the colons  of these  
patients.(14) 2) Elevated circulating pro -inflammatory cytokines observed in cirrhosis increase the  
permeability of the blood -brain barrier to ammonia leading to poor cognition.(15 -18) Investigators have  
found Faecalibacterium prausnitzi , a commensal  with robust anti -inflammatory properties, is diminished  
in cirrhotic patients compared to healthy controls.(19 -22) 3) Taxa with robust short -chain fatty acid  
(SCFA) production, essential to  enterocyte  health and maintenance of  intestinal gap junctions, are  
diminished in cirrhotic patients, which may contribute to impaired intestinal permeability to neurotoxic  
bacterial products.(23) In a rat model, oral administration of SCFAs reduced enterotoxin -induced liver  
injury  and TNF-α levels.(24)  Based  on this existing  evidence , we hypothesize  that  manipulation  of the gut 
microbiome could improve cognitive deficits in cirrhotic patients by influencing the pathways linking  
the gut to HE and prevent  recurrent  OHE.  
 
VE303 is a promising treatment for HE. First, VE303 is designed to treat C. difficile infection (CDI), and HE  
has previously  been  successfully  treated  with  another  microbiome  therapy  for CDI – FMT.  Second,  VE303  
contains organisms with robust SCFA production, one of the suspected pathways by which microbiome  
therapies  could  improve  intestinal  permeability  and therefore  HE. Third,  VE303  strains  induce  conversion  
of primary bile acids into secondary bile acids, which has the potential downstream impact of reduced  
intestinal permeability. Fourth,  VE303 strains induce T -regulatory cells,  which play a critical role in  
maintaining  intestinal homeostasis  by controlling  inflammation.(25, 26)  
 
  2.3 RISK/BENEFIT  ASSESSMENT   
 
Psychological  Risk 
Participation in research may lead to undesired changes in thought process or emotion. Patients may  
experience discomfort when being asked questions about their medical history that they deem to be  
private. Cognitive testing may create stress or frustration for patients. Finally, stool sample collection is  
psychologically  troubling  to some.  
2.3.1  KNOWN  POTENTIAL  RISKS  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
6  
  
 
Risks  of VE303  
Thus far, VE303 has been given to approximately 100 people in clinical trials. The known or expected 
risks of the study medication are:  
• Common (happens in 10 or more patients out of 100): diarrhea, nausea, and belly pain  
• Uncommon (fewer than 10 patients out of 100): belly bloating, headache, elevated lipase (an 
enzyme from the pancreas), constipation, vomiting, and chills.  
Most cases of abdominal distension and nausea were attributed to oral vancomycin pretreatment 
rather than VE303.  
Please see the Investigator Brochure for further details regarding treatment emergent adverse events.  
Risks  of oral Vancomycin  
From information obtained in the oral vancomycin capsule package insert, the most common adverse  
reactions (≥ 10%) were nausea (17%), abdominal pain (15%), and hypokalemia (13%). Nephrotoxicity has  
occurred following oral vancomycin capsule therapy, though not common, with those 65 years old and  
older at highest risk. This toxicity was reported in patients with colitis, which will be excluded in our  
cohort.  We will monitor  serum  creatinine  in all patients  before  and after  vancomycin  administration.  
Ototoxicity has also occurred in patients receiving oral vancomycin capsule, though not common.  
Finally,  there  is increased  risk of the development  of drug  resistant  bacteria.  
 
Risks  Related  to Study  Procedures  
Subjects  may  develop  a bruise,  feel light -headed,  faint  or develop  an infection  related  to study  blood  
draws.  
 
This is the first study of VE303 in this patient population, so it is unclear if VE303 will provide any  
benefit.  Potential  benefits  of VE303  include  improvement  in cognitive  function  and prevention  of 
recurrence  of OHE.  
 
HE is a common complication from cirrhosis, in desperate need of more effective and tolerable  
treatments. Discovery of one such novel treatment could benefit thousands of future patients. VE303  
has demonstrated  a good  safety  profile  in healthy  volunteers  and individuals  with  CDI. VE303  contains  
only known commensal bacterial strains, and therefore poses no known risk for harm to patients with  
cirrhosis. HE is a condition associated with considerable risk itself; therefore, we believe that the  
potential  for benefit  with  this trial outweighs  the potential risks.  
 
  3 OBJECTIVES  AND  ENDPOINTS   
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION  FOR ENDPOINTS  
Primary    
Primary Safety Objective is  
to determine if VE303  
increases the rate of  
serious adverse events  
(SAEs).  Primary Safety  
Endpoint : Number of  
SAEs  up to Week  6. This is the first trial of VE303 in cirrhosis and  
safety  assessment  is a primary  objective.  
2.3.2  KNOWN  POTENTIAL  BENEFITS  
2.3.3  ASSESSMENT  OF POTENTIAL  RISKS  AND  BENEFITS  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
7  
 Primary Efficacy Objective  
is to determine  if VE303  Primary Efficacy  
Endpoint : Change  in The neurological impairment associated with  
HE involves  deficits  in several domains:  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
8  
  
OBJECTIVES  ENDPOINTS  JUSTIFICATION  FOR ENDPOINTS  
improves cognitive  
function.  psychometric HE score  
(PHES) from pre - 
vancomycin  to Week  6. attention, visuospatial, fine motor skills and  
memory. The ideal tool is a validated  
assessment that comprehensively assesses  
these domains for impairment.(27) The  
Psychometric  Hepatic  Encephalopathy  Score  
(PHES):  
• Battery of 5 paper -pencil tests that  
evaluate cognitive and psychomotor  
processing speed and visuomotor  
coordination.  
• 15-20 minutes  to complete  
• Good external validity, endorsed by  
major specialty organization (ISHEN)  
and developed specifically to assess  
minimal HE.  
• Scores on each subtest are assigned  
values  based  on age-related  norms  
Secondary    
Secondary Objective 1:  
Determine if VE303  
reduces OHE  
hospitalizations  in the 6 
months post - 
administration.  Secondary Objective 1:  
OHE hospitalizations in  
the 6 months post - 
administration (through  
Week  26). Recurrent OHE is associated with  
considerable morbidity and mortality, and  
therefore  has significant  clinical  importance.  
 
Secondary Objective 2:  
Evaluate the durability of  
cognitive  effect  of VE303.   
Secondary Objective 2:  
Change in PHES from  
pre-vancomycin to 6  
months post -VE303  
(through  Week  26).  
It is important  to understand  the durability of  
the intervention  being  studied.  
Secondary Objective 3:  
Evaluate the safety and  
tolerability of VE303 by  
cirrhotic  patients.  Secondary Objective 3:  
Difference between  
intervention  and control  
arm in all  adverse  
events  Safety  is critical to  evaluate  with  an 
investigational  drug.  
Secondary Objective 4:  
Determine if VE303  
changes the microbiome  
composition  in cirrhosis.  Secondary Objective 4:  
Change in microbiome  
composition. Calculate  
beta  diversity  between  
stool  collection  time  In order to understand the mechanisms  
underpinning the (potential) therapeutic  
effect of VE303 in HE, the microbiome  
changes  associated  with  VE303  and improved  
cognition  must  be evaluated.  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
9  
  
OBJECTIVES  ENDPOINTS  JUSTIFICATION  FOR ENDPOINTS  
 points. We will perform  
metagenomic  
sequencing on stool to  
assess  this.   
 
Secondary Objective 5:  
Determine if VE303 strains  
colonize  cirrhotic  patients.  Secondary Objective 5:  
VE303 strain  
colonization, VE303  
strain -specific marker  
sequences will be  
detected in the stool  
over time. We will  
perform metagenomic  
sequencing  on stool  to 
assess  this.   
The VE303 component strains have variable  
susceptibility to rifaximin. Monitoring VE303  
strain  colonization  in this study population  is 
critical to understanding the associations  
between  VE303  and improved  cognition.  
Tertiary/Exploratory    
Determine if VE303  
changes  serum  and stool  Change  over  time  in: 
1. Venous  and In order  to better  understand  the mechanism  
underpinning  the gut-liver -brain  connection.  
biomarkers  to explore  the fecal  ammonia   
mechanism  behind  the 2. Inflammatory   
gut-liver -brain  connection.  cytokines  
including  IL-1,  
 IL-6, IL-18, CRP,   
 fecal   
 calprotectin,   
 TNF-alpha   
 3. Endotoxin  (LPS)   
 4. Serum  and fecal   
 short -chain  fatty   
 acids   
 5. Fecal  bile acids   
 6. Speech   
 assessment   
 
  4 STUDY  DESIGN   
 
  4.1 OVERALL  DESIGN   
 
We are performing a single -center randomized, placebo -controlled, double -blinded trial of VE303 to  
prevent  OHE  recurrence  and improve  cognition  in patients  with  a history  of overt  hepatic  encephalopathy  
(OHE).  Our hypothesis is that VE303 will  safely and effectively prevent OHE  episodes and improve  
cognitive  function,  while  changing  the fecal  microbiome  in patients  with  a history  of HE. Subjects  will be 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
10  
  
randomized 2:1 to VE303 vs placebo. There will be no stratification. Both study arms will receive 5 days  of 
oral Vancomycin.  The intervention  arm will receive  5 VE303  capsules  daily  for 14 days  and the placebo  arm 
will receive 5 placebo capsules daily for 14 days. VE303 or placebo will start on the last day of  Vancomycin 
(Day 1). Follow up will occur at Day 8, Day 14, and Weeks 4, 6, 10, 14, 18 and 26 after the  start  of VE303  
or placebo.  Depending  on results  from  the initial  pilot  study,  further  study  of different  dose,  duration,  and 
the necessity  of pre-VE303  Vancomycin  may  be required.  
 
  4.2   SCIENTIFIC  RATIONALE  FOR STUDY  DESIGN   
This study will be the first investigation of safety and efficacy of VE303 in patients with cirrhosis. As such,  
we plan to perform this phase 2a study. Placebo capsules for VE303 exist, and will provide an excellent  
control  for our experiment.  Performing  a randomized  placebo -controlled  study  will provide  a high  level  of 
evidence  concerning  the safety  and efficacy  of VE303.  
 
In a study of healthy volunteers, pre -treatment with vancomycin was necessary for durable colonization  
of VE303 strains. In fact, VE303 strains were detected in recipients 1 year later when vancomycin pre - 
treatment was used. In order to optimize VE303 engraftment, VE303 must be administered as soon as  
possible after Vancomycin has  been given.  Delaying VE303 by  even 1  or 2 days after  Vancomycin  
completes  can significantly  reduce  engraftment.  For that reason,  we plan  to administer  VE303  (or placebo)  
on the 5th day of Vancomycin; in other words, overlapping with Vancomycin for one day. If the patient  
unexpectedly requires rescheduling (for example due to a snow storm), we will allow f or VE303 (or  
placebo) delivery on the day after Vancomycin completes, but will make strong efforts to dose VE303 (or  
placebo)  exactly  on Day 1 (last  day of Vancomycin).  
 
If only the VE303 -treatment arm received pre -treatment Vancomycin,  two substantial study design  
problems  would  emerge:  1) the experiment  would  no longer  be blinded  as both  patients  and investigators  
would be aware of their grouping, introducing potential observer bias; 2) any comparison of outcomes  
between the placebo and treatment arms would be confounded by the use of vancomycin in only the  
treatment  group.  It would  be impossible  to disentangle  which  outcomes  were  related  to vancomycin  and 
which were related to VE303. Finally, oral vancomycin has very few side effects or risks. As such, we plan  
to administer  pre-treatment  vancomycin  to all participants.  
 
All participants will remain on both lactulose and rifaximin at their prescribed dose and frequency  
throughout  the study.  First,  maintaining  both  lactulose  and rifaximin  in all patients  will prevent  
confounding  or the need  for stratification,  which  would  have  been  necessary  if there  were  heterogeneity  
in the active HE treatment of participants. Second, withdrawing lactulose and/or rifaximin prior to trial  
participation would risk precipitating an OHE event, which would pose too large a risk to participants.  
Third, rifaximin has weak anti -microbial properties and does not appear to impact microbial abundance  
in cirrhosis  (rather  impacts  microbial function).(6)  
 
  4.3   JUSTIFICATION  FOR DOSE   
In a Phase  1 study  of healthy  volunteers,  14 days  of 10 daily  VE303  capsules  achieved  the greatest  number  
of VE303  strains  at 1 year  of follow  up. Since  the completion  of that study,  Vedanta  now  has capsules  that 
contain double the quantity of the original capsules. Therefore, only 5 capsules are now needed to yield  
the same dose. This dosing regimen had a tolerable and benign safety profile. Patients with cirrhosis are  
more  likely  than  individuals  with  no cirrhosis  to require  multiple  doses  of FMT  to treat  refractory  CDI.(28)  
This increased  treatment  requirement  is likely  due to the entrenched  dysbiosis  characteristic  of cirrhosis.  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
11  
  
As such,  we suspect  this 14-day dosing  regimen  is the most likely  to overcome  the dysbiosis  of cirrhosis,  
safely,  and lead  to positive  clinical outcomes.  
 
In the placebo  arm,  we will administer  placebo  capsules  on the same  schedule  as the VE303  arm,  in order  
to maintain  blinding.  
 
Depending  on results  from  the initial  pilot  study,  further  testing  of different  dose  and duration,  and need  
for vancomycin  pre-treatment  may  be required.  
 
  4.4 END  OF STUDY  DEFINITION   
 
A participant is considered to have completed the study if he or she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of Activities (SoA),  
Section 1.3. The end of the study is defined as completion by the last participant of the last visit or  
procedure  shown  in the SoA section.  
 
  5     STUDY  POPULATION   
Eligible  patients  have  cirrhosis,  at least  one prior  episode  of OHE  any time  in the past  and no current  OHE.  
Only patients consistently taking lactulose and rifaximin are enrolled to limit confounding. Additional  
exclusion  criteria  include  ongoing  use of systemic  antibiotics  or immunosuppression.  
  5.1   INCLUSION  CRITERIA   
In order  to be eligible  to participate  in this study, an  individual must  meet  all of  the following criteria:  
1. Able  to provide  consent,  with  signed  and dated  informed  consent  form  
2. Stated  willingness  to comply  with  all study  procedures  and availability  for the duration  of the 
study, including  ability  to store  VE303  or placebo  in home  fridge  
3. Male  or female, aged  18 through  75 years  old 
4. Diagnosis  of cirrhosis  based  on liver  biopsy,  imaging,  or evidence  of clinical  decompensation  
5. History  of at least  one episode  of overt  HE any  time  in the past  
• Defined  by West  Haven  Criteria  Grades  II to IV 
• Can be precipitated  HE episode  
6. Prescribed  both  lactulose  and rifaximin,  and compliant  with  this treatment  
a. Lactulose:  At least  one dose/day  at least  5 days  per week  
b. Rifaximin:  At least  one dose/day at  least  5 days  per week  
7. Sexually active women of childbearing potential enrolled in the study must agree to use a highly  
effective method of contraception, other than oral contraceptive pills (defined in Appendix 1)  
until  3 months  after  the last dose  of the study  product.  
 
  5.2 EXCLUSION  CRITERIA   
An individual who  meets  any of the following  criteria  will be  excluded  from  participation  in this study:  
 
1. Current  episode  of overt  HE as defined  by West  Haven  Criteria  Grades  II to IV 
2. Current  infection  including  C difficile  
3. Variceal bleeding  in the last 4 weeks  
4. Gut-absorbable  or intravenous  antibiotic  therapy  in the last 28 days  
5. Anticipated  antibiotics  in the coming  4 weeks  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
12  
  
6. Fecal  microbiota  transplant  in the last 6  months  
7. Use of probiotics  in the last 2 weeks  
8. Alcohol or  illicit  drug  intake  in the last 4 weeks  
o By history  
o Alcohol  use will be characterized  as >1 alcoholic  drink  / week  
9. Primary  sclerosing  cholangitis  as etiology  of liver  disease,  as prior  literature  has suggested  these  
individuals  have  a unique  microbiome  
10. History of inflammatory bowel disease, short gut, gastrointestinal tract fistulas, intestinal  
ischemia,  or any form  of ongoing  colitis  
11. Prior  diagnosis  of dementia  or other  primary  neurocognitive  disorder  
12. Known  hypersensitivity/allergy/intolerance  to Vancomycin  and any ingredients  of VE303:  
sucrose,  histidine,  yeast  extract,  cysteine,  metabisulfite,  and microcrystalline  cellulose  
13. History  of Roux -en-Y Gastric  bypass  
14. Any gastrointestinal  surgery  in the last year  
15. Substantial immune compromise/deficiency (e.g., uncontrolled HIV, active immune suppressive  
therapy  including  high  doses  of corticosteroids  or medications  to prevent  graft  rejection,  recent  
myeloablative  therapy, sustained  neutropenia)  
16. Pregnancy  or breast  feeding  
17. Use of oral contraceptive  pills in the last month  or planned  use during  the study  period  
18. MELD  > 20 
19. History  of spontaneous  bacterial  peritonitis  
20. Hemodialysis  in the last 28 days  
21. Other  significant  laboratory  abnormalities:  
o Serum  creatinine  > 2.0 mg/dL  
o Hemoglobin  < 8 g/dL  
o Serum  sodium  < 125 mmol/L  
o Serum  potassium <  2.5 mmol/L  
22. Placement  of a portosystemic  shunt  or transjugular  intrahepatic  portosystemic  shunt in  the last 
3 months  (permissible  if placed  >3 months  before  enrollment)  
23. Unstable  doses  of opiates, benzodiazepines  or other  sedating  medication  
o Chronic  methadone  or low dose  benzodiazepines  (for example)  is acceptable  
 
  5.3 LIFESTYLE  CONSIDERATIONS   
Not applicable  
 
  5.4 SCREEN  FAILURES   
 
Screen failures are defined as participants who consent to participate in the clinical trial but do not  
receive any study drug, including vancomycin, VE303 or placebo. A minimal set of screen failure  
information is required to ensure transparent reporting of screen failure participants, to meet the  
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to  
queries from regulatory authorities. Minimal information includes demography, reasons for screen  
failure,  and eligibility  criteria.  
 
Individuals  who  do not meet  the criteria  for participation  in this trial (screen  failure)  because  of a recent  
clinical  event  on the list of exclusion  criteria  may  be rescreened. Rescreened  participants  should  be 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
13  
  
assigned  the same  participant  number  as for the initial screening.  Subjects  will be  limited  to one re- 
screen.  
 
  5.5 STRATEGIES  FOR RECRUITMENT  AND  RETENTION   
Subjects will be identified through multiple mechanisms. First, University of Michigan hepatologists will  
be asked to review their patient panel for potential candidates. Second, the schedule of patients  
presenting to University of Michigan Liver Clinic will be reviewed in advance to screen for potential  
eligible patients. If an eligible patient is identified, the hepatology provider will be notified. If the  
hepatology provider agrees that the patient is an appropriate potential subject, the subject will be  
approached after their clinic visit. Finally, a flier will be posted in the University of Michigan Liver Clinic.  
Potential subjects’ hepatologist will be approached for permission to have study staff speak with the  
subjects.  
 
Subjects  will receive  a $50 check  for each  in-person  screening  or study  visit.  
 
  6 STUDY  INTERVENTION   
 
  6.1 STUDY  INTERVENTION(S)  ADMINISTRATION   
 
 
VE303 is a living biotherapeutic product (LBP) consisting of 8 well characterized, clonally -derived,  
nonpathogenic, nontoxigenic strains of Clostridia. The composition of VE303 was rationally selected  
based  on strain  and consortia -specific  properties  for their  association  with  healthy  human  microbiomes,  
lack of C. difficile -related dysbiosis, and lack of overt pathogenic features. Each of the 8 bacterial strains  
in VE303 produce SCFAs, which are reduced in patients with cirrhosis and may influence intestinal  
barrier  function  and the development  of HE. 
 
 
All enrolled  participants  will receive  oral vancomycin  125 mg QID for 5 days  prior  to randomization.  The 
purpose of this pretreatment is to reduce total bacterial biomass and allow for optimal VE303 strain  
colonization  (see VE303  investigator  brochure  for further  detail  on rationale).  
 
The patients randomized to VE303 will receive 14 days of 5 oral VE303 capsules, taken once daily. The  
patients randomized to placebo will receive 14 days of 5 oral placebo capsules, identical in appearance  
to VE303,  taken  once  daily. The  VE303  or placebo  regimens  will start  on the last day of Vancomycin  (Day  
1), but could be given up to the day after Vancomycin stops if there are unavoidable schedule changes.  
Patients  will be  asked  to take  the study  drug at  approximately  the same  time  each  day.  
 
VE303 and placebo capsules will be administered orally once daily with a beverage of choice that  
contains no solid food substances – water is ideal, but any clear or carbonated beverage may be used.  
Beverages  should  be at room  temperature, cool,  or warm  (not hot).  
 
In addition,  patients  cannot:  
6.1.1  STUDY  INTERVENTION  DESCRIPTION  
6.1.2  DOSING  AND  ADMINISTRATION  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
14  
  
- Consume  food  or fast-acting  antacids  (calcium -, aluminum -, or magnesium -containing  products  
such  as Tums  or Maalox)  for at least  1 hour  before  or after  study  drug  ingestion  
- Ingest  histamine -2 receptor  antagonist  (ranitidine,  famotidine,  etc) within  12 hours  before  or 1 
hour  after  study  drug  ingestion  
- Ingest  proton -pump  inhibitor  (omeprazole,  pantoprazole,  etc) within  the 12 hours  before  or 1 
hour  after  study  drug  ingestion.  
 
  6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY   
 
 
Study intervention and placebo product will be shipped from PCI Pharma Services (Rockford IL), to the  
University of Michigan Research Pharmacy. The University of Michigan Research Pharmacy will confirm  
receipt of the study products with Vedanta. The University of Michigan Pharmacy will store the study  
products in a 5°C +/ - 3°C fridge. This fridge will be in the locked premises of the Research Pharmacy, and  
only accessible by Pharmacy staff. A log will be kept detailing receipt, dispensing, and destruction or  
return to Vedanta of study product, by Pharmacy staff and according to University of Michigan Research  
Pharmacy  standard  operating  procedure.  
 
Vancomycin will be supplied by the University of Michigan Research Pharmacy. Information on  
formulation,  storage, and  stability  can be found  in the package  insert.  
 
 
VE303 consists of 8 different Clostridial strains, each manufactured separately. The quantity of each  
strain  is proportioned  to assure  a specific  per-strain  per-capsule  titer. The  8 strains  are blended  together  
with a micro -crystalline cellulose flow agent and placed in enteric capsules. The capsule also contains  
sucrose, histidine, yeast extract, cysteine, and sodium metabisulfite as excipients. The capsule will  
deliver 1.6x109 CFU per strain per capsule. The capsules are designed to pass through the stomach and  
then release the strains in the upper small intestine. Further details are provided in the Investigator  
Brochure  and Pharmacy  Manual.  
 
Placebo capsules contain micro -crystalline cellulose and are visually identical to VE303 capsules.  
However,  placebo  capsules  will not contain  any bacterial  strains  or formulation  buffer  used  in the VE303  
drug  product.  
 
 
VE303 is stable when stored in the sealed and capped bottle at 5°C ± 3°C. The University of Michigan  
Research Pharmacy will store both the VE303 and placebo capsules in a fridge under these conditions  
until dispensed to the patient. When dispensed to the patient, the study drug will be contained in the  
capped bottle, in a lunch box with freezer packs. The patient will ingest the VE303 or placebo capsules  
on Day 1 under the observation of study staff and then will be instructed to transport the study drug  
directly to their home.  They will keep the capsules in a contained box within their fridge, clearly labeled  
with the statement “Caution: New Drug — Limited by Federal (or United States) law to investigational  
use.”,  and only  for the subject’s  use. 
6.2.1  ACQUISITION  AND  ACCOUNTABILITY  
6.2.2  FORMULATION,  APPEARANCE,  PACKAGING,  AND  LABELING  
6.2.3  PRODUCT  STORAGE  AND  STABILITY  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
15  
  
 
The study  product is  produced  to the  point of  capsule  formation  by the manufacturer.  This study  team  
at University  of Michigan  will not be involved  in capsule  creation.  See the Pharmacy  Manual  for further  
detail  regarding  study  drug  preparation.  
 
  6.3 MEASURES  TO MINIMIZE  BIAS:  RANDOMIZATION  AND  BLINDING   
Subjects who have signed informed consent and meet enrollment criteria will be scheduled for a series  
of study visits. The first treatment study visit must take place within 3 weeks (or 21 days) of signing  
informed consent. If subjects are unable to present for the first treatment study visit within 21 days, we  
will re -verify eligibility including repeating lab testing and physical exam. Subjects will be randomized  
once they have signed informed consent and completed 4 days of oral vancomycin (5 days total of  
vancomycin  but the 5th day overlaps  with  study  drug  initiation).  Study  staff  will remain  blinded  to subject  
randomization  until the  final subject reaches the primary safety and efficacy endpoints (Visit 6). After 
this point, a portion of the study team will be unblinded to evaluate the primary outcome results. A 
portion of the study team , including the PI Dr. Bloom, will remain blinded until the end of the study. 
Only blinded study team members will be involved in evaluating adverse events, including with regards 
to possible relatedness  to study drug . 
 
Randomization will be performed by the University of Michigan pharmacy. The study blind may be  
broken if a subject has received study drug and developed a serious adverse event that was potentially  
related  to study  drug.  
 
  6.4 STUDY  INTERVENTION  COMPLIANCE   
To ensure drug accountability, subjects will be asked to show study staff their study drug pill bottle  
(virtually) on Day 8 and (in person) on Day 14. On Day 14, the subjects will be asked to bring the bottle  
of study drug to demonstrate it is empty (i.e. all of the study drug had been consumed). Subjects will  
also be asked  about  study  drug  compliance  on Days  8 and 14. 
 
There will be an independent data safety monitoring board (DSMB) composed of a hepatologist, an  
infectious  disease  specialist  and a statistician  not involved  in the study.  That  group  will review  AEs,  SAEs,  
and enrollment.  
 
Safety  monitoring  will be ongoing  throughout  the protocol.  Dr. Bloom  or a co-investigator  will evaluate  
the subjects at the Day 1 visit, Day 14 visit, Week 6 visit, and final study visit (Week 26). The PI will  
review all study visit documents, including labs, within 2 business days of the tests results. AEs will be  
thoroughly  assessed  after  each  treatment  visit by study  investigators  and documented  in the source.  
The PI and study  staff will  send  blinded  aggregate  reports  on safety  events  to co -investigators  and the 
DSMB  on a monthly  basis.  
 
The PI will meet with study staff regularly to review study progress, subject status, and logistical issues.  
We will comply with the reporting of any IND safety reports according to FDA or other federal  
guidelines. The study coordinator will work with the physician investigators to process the report of  
these  events  as they  happen.  
 
Study monitoring will be performed by the University of Michigan Institute of Clinical and Health  
Research (MICHR).  Routine monitoring will be scheduled at appropriate intervals, with more frequent  
visits occurring at the beginning of the study.  A site initiation visit will take place, followed by routine  
monitoring  visits.  
6.2.4  PREPARATION  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
16  
  
In addition  to formal  monitoring  visits,  Dr. Bloom  will be regularly  monitoring  the study  documents  and 
meeting  with  study  staff  to review  the status  of the study.  Dr. Bloom  will ultimately  be responsible  for 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
17  
  
protecting the rights, safety and welfare of all subjects enrolled in this study. In the case of Dr. Bloom’s  
absence,  monitoring  responsibilities  will be delegated  to one of the study  sub-investigators  listed  in the 
IRB application.  
 
  6.5 CONCOMITANT  THERAPY   
For this protocol, a  prescription  medication  is defined  as a medication  that can be prescribed  only  by a 
properly authorized/licensed clinician. Medications to be reported in the Case Report Form (CRF) are  
concomitant  prescription  medications,  over -the-counter  medications  and supplements.  
 
To pass screening, subjects must report compliance with lactulose and rifaximin (at least one dose/day,  
5 days per week for each of these medications), no gut -absorbable or intravenous antibiotics in the last  
28 days, and antibiotic therapy cannot be anticipated in the coming 4 weeks. Subjects cannot be on  
immunosuppressive medications, or unstable doses of opiates, benzodiazepines or other sedating  
medications.  These  medications  will be  checked  at each  in-person  study  visit.  
 
In addition,  patients  cannot:  
- Consume  food  or fast-acting  antacids  (calcium -, aluminum -, or magnesium -containing  products  
such  as Tums  or Maalox)  for at least  1 hour  before  or after  study  drug  ingestion  
- Ingest  histamine -2 receptor  antagonist  (ranitidine,  famotidine,  etc) within  12 hours  before  or 1 
hour  after  study  drug  ingestion  
- Ingest  proton -pump  inhibitor  (omeprazole,  pantoprazole,  etc) within  the 12 hours  before  or 1 
hour  after  study  drug  ingestion.  
 
 
The study will not supply rescue medication for overt HE. Need for rescue would be triggered by an  
episode of overt HE necessitating emergency room visit or hospital admission. The need for rescue  
medication  will not be made  by study  staff, rather  by treating  providers. The  use of rescue  medication  is 
allowable at any time during the study and will not be delayed for study purposes. The date and time of  
rescue medication administration as well as the name and dosage regimen of the rescue medication  
must  be recorded.  
 
If systemic antibiotics are deemed necessary during this study for a presumed infection, and VE303  
component  bacteria  may  be implicated,  consideration  should  be given  to the use of one or more  of the 
5 following broad -spectrum antibiotics, to which all of the bacteria contained in VE303 are susceptible  
(based on in vitro testing – refer to the VE303 Investigator Brochure for more details), according to  
institutional  standard  of care  guidelines  regarding  antibiotic  dose, route  and frequency:  
- Piperacillin/tazobactam  
- Amoxicillin  clavulanate  
- Imipenem  
- Metronidazole  
- Tigecycline  
 
This list of antibiotics will be reported to health care personnel if admission to the hospital or emergency  
department is warranted. Note: if VE303 component bacteria are implicated in an intestinal infection  
and an oral antibiotic  is desired,  oral metronidazole  or amoxicillin  clavulanate  should  be considered.  
6.5.1  RESCUE  MEDICINE  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
18  
  
 
 
  7.1 DISCONTINUATION  OF STUDY  INTERVENTION   
We define  temporary  study -wide  halting  rules  as follows:  
a. Any serious  adverse  event  (SAE)  assessed  as probably  or definitely  related  to study  treatment.  
b. Any suspected  or proven  infection  assessed  as probably  or definitely  related  to study  treatment.  
c. Two  or more  subjects  with  the same, or  similar, Grade  3 or higher  adverse  event  considered  at 
least  possibly  related  to the oral vancomycin  and/or  study  drug  (VE303  or placebo).  
Temporary  study -wide  halt could  entail:  
a. Stop  new  enrollment  but allow  enrolled  patients  to continue  treatment  
b. Stop  new  enrollment  and stop  all dosing  
 
In the event of an SAE, suspected or proven infection, or two or more subjects with the same or similar  
Grade 3 or higher AE, Dr. Bloom will assess the relatedness to study treatment.  If Dr. Bloom assesses the  
event as probably or definitely related to study treatment, she will report the event to the data safety  
monitoring board (DSMB). The DSMB will review the case, make its determination about relatedness,  
and if deemed  necessary,  recommend  a temporary  study -wide  halt.  This recommendation  may  apply  to 
(a) new  enrollment  only, or  (b) both  new  enrollment  and participants  already  being  treated  in the study.  
This event  will be  reported  to Vedanta  as well as  the IRB according  to the  IRB reporting  guidelines.  
 
Study -wide  halt will continue  until relatedness  to study  treatment  has been  determined  in consultation  
with (blinded) Vedanta personnel. Discontinuation from oral VE303 capsules does not mean  
discontinuation from the study, and remaining study procedures should be completed as indicated by  
the study  protocol.  
 
Once relatedness is determined by the DSMB and a decision has been made regarding a study halt, next  
steps, including plans to lift a study halt, would be discussed and agreed upon by Dr. Bloom, DSMB, in  
consultation with (blinded) Vedanta representatives, and the University of Michigan IRB. If the decision  
is made to discontinue participation in the study, discontinuation from oral VE303 capsules does not  
mean discontinuation from the study, and remaining study procedures should be completed as  
indicated  by the study  protocol.  
 
The data  to be collected  at the time  of study  intervention  discontinuation  will include  the following:  
• Stool  sample  for culture  and sequencing  
• Routine  blood  tests,  including CMP,  CBC,  INR 
• Cognitive  testing by  PHES  
 
In addition, an interval analysis will be performed when the 9th patient reaches Day 14 and has  
completed  VE303  or placebo  intervention.  Specifically,  the rate of SAEs,  with  a special focus  on 
infection -related  SAEs,  will be compared  between  VE303  and placebo  groups  by the DSMB.  If they  deem  
the safety assessment to be satisfactory, the study will continue to complete enrollment of 18 subjects.  
We will briefly pause enrollment of the 10th patient, until this determination is made and restart  
enrollment  immediately  if there  is no important  safety  concern  related  to VE303.  
7 STUDY  INTERVENTION  DISCONTINUATION  AND  PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
19  
  
  7.2 PARTICIPANT  DISCONTINUATION/WITHDRAWAL  FROM  THE  STUDY   
 
Participants  are free to withdraw  from  participation  in the study  at any time  upon  request.  
An investigator  may  discontinue  or withdraw  a participant  from  the study  for the following  reasons:  
 
• Significant  study  intervention  non-compliance  
• If any clinical  adverse  event  (AE),  laboratory  abnormality,  or other  medical  condition  or situation  
occurs such that continued participation in the study would not be in the best interest of the  
participant.  This includes, but  is not limited  to: 
o Single serious adverse event considered at least possibly related to the oral vancomycin  
and/or  study  drug  (VE303  or placebo)  treatment  regimen  
o Grade  3 or higher  adverse  event  considered  at least  possibly  related  to the oral 
vancomycin  and/or  study  drug  (VE303  or placebo)  treatment  regimen  
o Transmission  of any infection  from  VE303  
o Pregnancy  
• Disease  progression  which  requires  discontinuation  of the  study  intervention  
• If the participant meets an exclusion criterion (either newly developed or not previously  
recognized)  that precludes  further  study  participation  
• If there  is an interruption  in dosing:  
o If participants miss more than one day of vancomycin dosing, the investigator will  
withdraw  them  from  participation  and allow  them  to re-screen  and re-enroll  in the 
future.  
o If one day of vancomycin is missed on Day -4, -3, or -2, then the participant will resume  
vancomycin  and continue  the study  schedule.  
o If one day of vancomycin is missed on Day -1, the participant will be asked to take one  
extra day of vancomycin before randomization (so the next day is vancomycin only, and  
the day thereafter  is vancomycin  + study  drug)  
o If the participant misses 1 -2 days of VE303 or placebo, they will be instructed to  
continue  the intervention  and add those  doses  to the end of their  treatment  course  
o If the participant  misses  3 or more  days  of VE303  or placebo,  including  for 
hospitalization:  
■ If the interruption occurs on Days 12 -14, continue the study as previously  
scheduled.  Participants  will not  take  the remaining  capsules  in this situation.  
■ If the interruption occurs before Day 12 and they miss 3 or more days of study  
capsules, study capsules will not be resumed after the pause. They will continue  
all subsequent  visits.  Additional  subjects  may  be enrolled  to replace  this subject.  
 
The reason for participant discontinuation or withdrawal from the study will be recorded on the Study  
Withdrawal Case Report Form (CRF). Subjects who sign the informed consent form and are randomized  
but have  not received  the study  intervention  may  be replaced.  Subjects  who  sign the informed  consent  
form, and are randomized and have received the study intervention, and subsequently withdraw from  
the study before the primary endpoint, not due to an SAE, may be replaced. Subjects who sign the  
informed consent form, and are randomized and have received the study intervention, and  
subsequently  withdraw  from  the study due  to an SAE, will not  be replaced.  
 
  7.3 LOST  TO FOLLOW -UP  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
20  
  
A participant  will be considered  lost to follow -up if he or she fails to return  for 2 scheduled  visits  and is 
unable  to be contacted  by the study  site staff.  
 
The following  actions  must  be taken  if a participant  fails to return  to the clinic  for a required  study  visit:  
• The site will attempt  to contact  the participant  and reschedule  the missed  visit within  2 weeks  (1 
week for study visits during treatment phase) and counsel the participant on the importance of  
maintaining the assigned visit schedule and ascertain if the participant wishes to and/or should  
continue  in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every  
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary,  
a certified letter to the participant’s last known mailing address or local equivalent methods).  
These  contact  attempts  should  be documented  in the participant’s  medical  record  or study  file. 
• Should  the participant continue  to be unreachable,  he or she will be considered  to have  
withdrawn  from  the study  with  a primary  reason  of lost to follow -up. 
 
  8 STUDY  ASSESSMENTS  AND  PROCEDURES   
 
  8.1 EFFICACY  ASSESSMENTS   
 
The primary efficacy assessment is change in the Psychometric Hepatic Encephalopathy Score (PHES)  
from baseline (before vancomycin) to Week 6. PHES is a validated tool to measure hepatic  
encephalopathy  disease  activity.  
 
The neurological impairment associated with HE involves deficits in several domains: attention,  
visuospatial, fine motor skills and memory. Therefore, we must use validated assessment tools that  
comprehensively assesses this impairment. The Psychometric Hepatic Encephalopathy Score (PHES) is  
the ideal tool to  use. PHES  is: 
• Battery  of 5 paper -pencil  tests  that evaluate  cognitive  and psychomotor processing  speed  and 
visuomotor  coordination.  
• Takes  15-20 minutes  to complete.  
• Good external validity, endorsed by major specialist organization (ISHEN) and developed  
specifically  to assess  minimal HE.(27)  
• Scores on each subtest are assigned values based on age -related norms (1+ for scores better  
than  1 standard  deviation  (SD) above  the normal  mean  to -3 for  scores  more  than  3 SDs below  
the normal mean).  
• Combined  scores  vary  from  +6 to -18. 
 
The secondary efficacy assessment is number of OHE episodes up to Week 26 following study drug or  
placebo initiation. The presence of an OHE episode will be evaluated by the primary treating physician  
assessment  during  hospitalization, based  on the West  Haven  Criteria.  
 
Another secondary efficacy endpoint of this study will be change in PHES from pre -intervention  
assessment  (screening  visit)  to Week  26. 
 
As recommended  by ISHEN,  we will perform  a second  assessment  of HE activity:  the Stroop  test.  Stroop  
is also a well -validated test to screen and diagnose minimal HE.(29 -31) The test involves identifying the  
color  of the stimuli on  the screen  with  three  kinds  of increasingly  challenging  stimuli. The  test will be  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
21  
  
performed on a study iPad, which will be maintained during the study period. The Stroop test sends an  
automatic email to study staff with results when the test has been completed. This email will be printed  
and saved  as source  documentation.  
 
  8.2 SAFETY  AND  OTHER  ASSESSMENTS   
 
The following  assessments  will be performed  at screening  and at several  times  during  the study period  to 
monitor  safety  (see SoA):  
• Physical examination including neurological examination and volume assessment (for hepatic  
hydrothorax,  LE edema, and  ascites).  
• Vital signs including body weight, temperature, pulse, and blood pressure. Study coordinator  
will be provided with a normal range of vital signs and will immediately notify a study physician  
of vital signs  outside  the normal range.  
• Laboratory evaluations . A series of routine blood tests will be performed at screening and at 4  
points throughout the study, as demonstrated in the SoA. These tests will include a BMP, LFTs,  
CBC, and INR. Amylase and lipase levels will be checked on Visits 2, 4, and 6. These test results  
will be sent to the PI’s (Dr. Bloom) clinical inbox for immediate response. These blood tests will  
all be performed  by the University  of Michigan  core  lab facilities, in  compliance  with  CLIA.  
o There is the potential for systemic absorption of oral vancomycin, which can be  
nephrotoxic  at higher  levels.  Therefore,  the following  additional  monitoring  will be 
performed:  
■ If a patient’s screening labs were more than 14 days prior to planned  
vancomycin  initiation,  we will recheck  serum  creatinine  on Day -6 (2 days  prior  
to vancomycin  initiation).  
■ If at screening or on Day -6, the patient’s serum creatinine was 1.5 mg/dL to 2.0  
mg/dL  (patients  with  serum  creatinine  > 2.0 mg/dL  are excluded), these  patients  
will undergo an additional blood draw on Day -2 to check serum creatinine.  
Vancomycin will be stopped if creatinine on Day -2 has increased to > 2.0 mg/dL  
or increased by 0.3 mg/dL since screening or Day -6. Vancomycin will not be  
resumed and the patient will not be randomized to study drug or placebo. The  
patient  will continue  to be  monitored for  nephrotoxicity  but will  be 
discontinued  from  the trial.  
• Assessment of adverse events. Adverse event reporting will be documented by an adverse  
event reporting form on Days 1, 8, 14, Week 4, 6, 10, 14, 18 and 26 follow up visits. Adverse  
events will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) V.5.0.  
If an adverse event is identified and is at least possibly related to VE303, a more intensive  
monitoring schedule may be employed. The default will be a daily phone call (during weekdays)  
from study staff until the adverse event has resol ved or the participant is removed from the  
study. Depending on the severity of the adverse event, the PI may determine that phone calls  
every 2 or 3 days is appropriate. Conversely, the PI may determine that an in -office study visit is  
required  for further  evaluation.  
o We will actively  collect  the following  solicited  AEs from  patients:  
■ Diarrhea: This is challenging given that lactulose (a medication taken by all  
patients in the trial) purposefully creates loose and frequent stools. We will  
define diarrhea here as an increase in the number of bowel movements daily by  
2 or more, or  a noticeable  increase  in looseness  of stool.  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
22  
  
■ Constipation: For this study, we will define constipation as no bowel movements  
for 2 days  or more  (if this is a change  from  baseline).  
■ Nausea  
■ Abdominal distension: This is challenging given that abdominal ascites and  
lactulose  both  cause  abdominal  distension  in many  of these  patients  at baseline.  
We will define this as a noticeable increase in abdominal distention from  
baseline  or new  abdominal distension.  
■ Abdominal  pain  
■ Headache  
■ Chills  
■ Fever  (temperature  100.4  or greater)  
o We will give patients a thermometer and a diary to record solicited AEs. We will ask  
patients  to record  this list of solicited  AEs daily  in their  diary  from  Day 1 through  Day 21 
(during 14 days of study drug and for 7 days thereafter). Study staff will specifically  
inquire about the solicited AEs during study visits 2, 3, 4, and 5 and collect the diary at  
visit 6. 
o We will collect solicited and unsolicited AEs on separate forms. Solicited AEs will be kept  
in one large solicited AE case report form which will include all of a patients’ solicited AE  
data from Day 1 through Day 21. Solicited AE data will be entered into this form on  
study  visits  2, 3, 4, 5, and  6. 
o Unsolicited AEs will be captured on a different case report form. Unsolicited AEs could  
occur during days 1 -21 (while solicited AE recording is taking place) if they are a  
symptom not on the solicited list. If a symptom on the solicited AE list occurs after day  
21 (when  the patient  is no longer  being  asked  daily  to record  that symptom),  that will be  
recorded  as an unsolicited  AE. 
o In analysis, we  will present  the two types  of AEs separately.  
 
After the study screening visit, once all the screening assessments have been performed and resulted, a  
determination about screening failure or success will be made by the PI. The subject will be informed of  
the outcome  and the remaining  study  visits  will be  scheduled  if the subject  was a screen  success.  
 
If any of the above  safety  assessments  are abnormal,  the participant  will be informed  of the results  in a 
timely  manner.  
 
An interval analysis will be performed when the 9th patient reaches Day 14 and has completed VE303 or  
placebo intervention. Specifically, the rate of SAEs, with a special focus on infection -related SAEs, will be  
compared between VE303 and placebo groups by the DSMB. If the DSMB deems the safety assessment  
to be satisfactory, the study will continue to complete enrollment of 18 subjects. We will briefly pause  
enrollment of the 10th patient, until this determination is made and restart enrollment immediately if 
there  is no important  safety  concern  related  to VE303.  
 
  8.3 ADVERSE  EVENTS  AND  SERIOUS  ADVERSE  EVENTS   
 
8.3.1  DEFINITION  OF ADVERSE  EVENTS  (AE)  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
23  
  
Adverse  event  means  any untoward  medical  occurrence  associated  with  the use of an intervention  in 
humans,  whether  or not considered  intervention -related  (21 CFR 312.32 (a)).  
 
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of the  
investigator, it results in any of the following outcomes: death, a life -threatening adverse event,  
inpatient  hospitalization  or prolongation  of existing  hospitalization,  a persistent  or significant  incapacity  
or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth  
defect. An emergency room visit which does not lead to hospitalization will not qualify as an SAE unless  
other criteria are met. Important medical events that may not result in death, be life -threatening, or  
require hospitalization may be considered serious when, based upon appropriate medical judgment,  
they may jeopardize the participant and may require medical or surgical intervention to prevent one of  
the outcomes  listed  in this definition.  
 
 
For adverse events (AEs) not included in the protocol defined grading system, the following guidelines  
will be  used  to describe  severity.  
 
• Grade  1: Mild  – Events  require  minimal  or no treatment  and do not interfere  with  the 
participant’s  daily  activities.  
• Grade 2: Moderate – Events result in a low level of inconvenience or concern with the  
therapeutic  measures.  Moderate  events  may  cause  some  interference  with  functioning.  
• Grade 3: Severe – Events interrupt a participant’s usual daily activity and may require systemic  
drug therapy or other treatment. Of note, the term “severe” does not necessarily equate to  
“serious”.  
• Grade  4: Life threatening  
• Grade  5: Death  
 
All adverse  events  (AEs)  must  have  their  relationship  to study  intervention  assessed  by the clinician  who  
examines  and evaluates  the participant  based  on temporal  relationship  and his/her  clinical  judgment.  
The degree  of certainty  about  causality  will be graded  using  the categories  below. In  a clinical  trial,  the 
study  product  must  always  be suspect.  
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible  
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test  
result,  occurs  in a plausible  time  relationship  to study  intervention  administration  and cannot be  
explained  by concurrent  disease  or other  drugs  or chemicals.  
• Probably  Related  – There  is evidence  to suggest  a causal relationship,  and the influence  of other  
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within  
a reasonable time after administration of the study intervention, is unlikely to be attributed to  
concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on  
withdrawal.  
• Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event  
occurred  within  a reasonable  time  after  administration  of the trial medication).  However,  other  
8.3.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE)  
8.3.3  CLASSIFICATION  OF AN ADVERSE  EVENT  
8.3.3.1     SEVERITY  OF EVENT  
8.3.3.2      RELATIONSHIP  TO STUDY  INTERVENTION  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
24  
  
factors may have contributed to the event (e.g., the participant’s clinical condition, other  
concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it  
can be flagged as requiring more information and later be upgraded to “probably related” or  
“definitely  related”, as  appropriate.  
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose  
temporal relationship to study intervention administration makes a causal relationship  
improbable (e.g., the event did not occur within a reasonable time after administration of the  
study intervention) and in which other drugs or chemicals or underlying disease provides  
plausible  explanations  (e.g.,  the participant’s  clinical  condition,  other  concomitant  treatments).  
• Not Related  – The AE is completely  independent  of study  intervention  administration,  and/or  
evidence exists that the event is definitely related to another etiology. There must be an  
alternative,  definitive  etiology  documented  by the clinician.  
 
The causal  relationship  between  study  drug  administration  and adverse  events  will be assessed  based  
on several factors: First , the temporal relationship between drug administration and the adverse event.  
Adverse events that take place within 3 days of drug administration are more likely to be definitely,  
probably or possibly related. Second , in case of infectious adverse events, the isolated pathogen will  
clarify the likelihood of a causal relationship. VE303 contains exclusively Clostridial species. Third , the  
expert opinions of Drs. Bloom, Lok, an d Young. Dr. Lok is an international expert in hepatitis and end  
stage liver disease, and will be able to significantly contribute opinions on whether the AE represents  
progression of underlying disease or the intervention. Dr. Young is an international expert on the  
microbiome  and infectious  disease  and will  be able  to contribute  an opinion  regarding  the likelihood  
that the AE is related to VE303. We appreciate this may be a challenging determination.  As questions of  
relatedness arise in real time, a physician discussion between Dr. Bloom (sponsor investigator) and co - 
investigators Drs. Lok and Young will take place. Dr. Bloom will make the ultimate determination of  
relatedness, with input from Drs. Lok and Young. We will err on the side of caution in assessing events as  
related.  The DSMB will ultimately review AEs and SAEs and can request further investigation into  
determinations  and change  the ultimate  relatedness  determination.  
 
Dr. Bloom  will be responsible  for determining  whether  an adverse  event  (AE) is expected  or unexpected.  
An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent  
with the risk information previously described for the study intervention based on the protocol,  
informed  consent, vancomycin  package  insert,  and the VE303  investigator  brochure.  
 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of  
study  personnel  during  study  visits  and interviews  of a study  participant  presenting  for medical  care, or  
upon  review  by a study  monitor.  
 
All AEs including  local  and systemic  reactions  not meeting  the criteria  for SAEs  will be captured  on the 
appropriate case report form (CRF). Information to be collected includes event description, time of  
onset, clinician’s assessment of severity, relationship to study product (assessed by PI), and time of  
resolution/stabilization of the event. All AEs occurring while on study must be documented  
appropriately  regardless  of relationship. All  AEs will be followed  to adequate  resolution.  
8.3.3.3      EXPECTEDNESS  
8.3.4  TIME  PERIOD  AND  FREQUENCY  FOR EVENT  ASSESSMENT  AND  FOLLOW -UP 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
25  
  
Any medical condition  that is present  at the  time  that the  participant  is screened  will be  considered  as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any  
time  during  the study, it  will be  recorded  as an AE. 
 
Changes  in the severity  of an AE will be  documented  to allow  an assessment  of the duration  of the event  
at each level of severity to be performed. AEs characterized as intermittent require documentation of  
onset  and duration  of each  episode.  
 
A clinical research coordinator will record all reportable events with start dates occurring any time after  
informed consent is obtained until the last day of study participation (Week 26).  At each study visit, the  
research coordinator will inquire about the occurrence of AE/SAEs since the last visit.  Events will be  
followed  for outcome  information  until resolution  or stabilization.  
 
All SAEs will be reported from a clinical research coordinator to Dr. Bloom, or Dr. Lok if Dr. Bloom is  
unavailable,  within  24 hours.  All non-serious  AEs will be reported  to Dr.  Bloom  within  5 business  days.  
 
All SAEs will be reported from a clinical research coordinator to Dr. Bloom within 24 hours. Dr. Bloom  
will assess the relatedness to study treatment. If Dr. Bloom assesses the event as probably or definitely  
related to study treatment, she will report the event to the DSMB. The DSMB will review the case as  
outlined in the DSMB charter, make its determination about relatedness, and if deemed necessary,  
recommend  a temporary  study -wide  halt. This  event  will be  reported  to Vedanta  as well as  the IRB. 
 
The PI and study  staff  will send  blinded  aggregate  reports  on safety  events  including  all SAEs  to co- 
investigators  and the DSMB  on a monthly  basis.  
 
All serious adverse events (SAEs) will be followed until satisfactory resolution or until Dr. Bloom deems  
the event  to be chronic or  the participant  is stable.  
 
All SAEs will  be reported  to the IRB per current  institutional  standards.  
 
Dr. Bloom, with assistance from the University of Michigan Institute of Clinical and Health Research  
IND/IDE Investigator Assistance Program will be responsible for the reporting of any and all IND safety  
reports to the FDA as per the requirements outlined in 21 CFR 312.32. This includes reporting of all  
Serious Adverse Events (SAEs) that are both unexpected and related to the drug as soon as possible, but  
in no case later than 15 calendar days after the sponsor determines that the information qualifies for  
reporting. If the unexpected and related SAE is either fatal or life -threatening, then the SAE must be  
reported as soon as possible but in no case later than 7 calendars days after Dr. Bloom’s initial receipt of  
the information. A summary of all non -expedited safety reports will be submitted in the annual report.  
In addition,  Dr. Bloom  must  notify  FDA and all  participating  investigators in this  Investigational  New  
Drug  (IND)  of any safety  reports  of potential  serious  risks,  from  clinical  trials  or any other  source,  as soon  
as possible, but in no case later than 15 calendar days after Dr. Bloom determines that the information  
qualifies  for reporting.  
 
8.3.5  ADVERSE  EVENT  REPORTING  
8.3.6  SERIOUS  ADVERSE  EVENT  REPORTING  
8.3.7  REPORTING  EVENTS  TO PARTICIPANTS  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
26  
  
Participants will be informed of AEs and SAEs related to that participant as soon as they occur and  will 
be updated as more information around relatedness becomes available. Any incidental findings, such as  
laboratory findings, will be disclosed to the participant, as well as their hepatology provider and primary  
care physician. Participants will not be informed of their cognitive testing results; only insofar as  
whether  or not their  score  qualifies  them  to successfully  screen  into the study.  
 
NA 
 
If a woman becomes pregnant while in the study, the study drug will be discontinued and the team will  
request permission to follow the pregnant woman to her pregnancy outcome. The PI will notify the IRB  
and Vedanta  within  24 hours.  
 
  8.4 UNANTICIPATED  PROBLEMS   
 
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to  
participants or others to include, in general, any incident, experience, or outcome that meets all of the  
following  criteria:  
 
• Unexpected  in terms  of nature,  severity,  or frequency  given  (a) the research  procedures  that are  
described in the protocol -related documents, such as the Institutional Review Board (IRB) - 
approved research protocol and informed consent document; and (b) the characteristics of the  
participant  population  being  studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a  
reasonable possibility that the incident, experience, or outcome may have been caused by the  
procedures  involved  in the research);  and 
• Suggests that the research places participants or others at a greater risk of harm (including  
physical,  psychological,  economic,  or social  harm)  than  was previously  known  or recognized.  
 
The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review Board  
(IRB)  per current  institution  guidelines.  The UP report will include  the following  information:  
 
• Protocol  identifying  information:  protocol  title and number,  PI’s name,  and the IRB project  
number;  
• A detailed  description  of the event,  incident,  experience,  or outcome;  
• An explanation  of the basis  for determining  that the event,  incident,  experience,  or outcome  
represents  an UP; 
• A description  of any changes  to the  protocol  or other  corrective  actions  that have  been  taken  or 
are proposed  in response  to the UP. 
 
To satisfy  the requirement  for prompt  reporting,  UPs will be  reported  using  the following  timeline:  
 
• UPs that are serious  adverse  events  (SAEs)  will be reported  to the  IRB and to the sponsor  
investigator  within  2 days  of the investigator  becoming  aware  of the event.  
8.3.8  EVENTS  OF SPECIAL  INTEREST  
8.3.9  REPORTING  OF PREGNANCY  
8.4.1  DEFINITION  OF UNANTICIPATED  PROBLEMS  (UP)  
8.4.2  UNANTICIPATED  PROBLEM  REPORTING  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
27  
  
• Any other  UP will be reported  to the IRB and to the study  sponsor  within  7 days  of the 
investigator  becoming  aware  of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by an institution’s  
written reporting procedures), the supporting agency head (or designee), and the Office for  
Human Research Protections (OHRP) within 14 days of the IRB’s receipt of the report of the  
problem  from  the investigator.  
 
Participants  will be informed  of unanticipated  problems  as soon  as they  occur,  and will be updated  as 
more  information  around  relatedness  becomes  available.  
 
  9 STATISTICAL  CONSIDERATIONS   
 
  9.1 STATISTICAL  HYPOTHESES   
 
 
• Primary  Safety  Endpoint:  Number  of SAEs  from  initiation  of vancomycin  up to  Week  6. 
o Hypothesis:  The intervention  arm will not have  a higher  rate of serious  adverse  events.  
 
• Primary Efficacy Endpoint: Change in psychometric HE score (PHES) from pre -vancomycin to  
Week  6. 
o Null  hypothesis : The change  in psychometric  HE score  (PHES)  from  pre-vancomycin  to 4 
weeks post -treatment (Week 6) is equal in the VE303/study drug and placebo/control  
arms.  
o Alternative hypothesis : The change in psychometric HE score (PHES) from pre - 
vancomycin to 4 weeks post -treatment (Week 6) will be greater (and beneficial) in the  
VE303/study  drug  arm than  the placebo/control arm.  
 
• Secondary  Efficacy  Endpoint  1: number  of OHE hospitalizations  in the 6 months  following  study  
drug  administration  (up to Week  26) 
o Null hypothesis : Patients who undergo the study intervention (VE303) will have the  
same number episodes of OHE in the 6 months following drug administration compared  
to those  who  received  placebo.  
o Alternative hypothesis : Patients who undergo the study intervention (VE303) will have  
fewer episodes of OHE in the 6 months following drug administration than those who  
received  placebo.  
 
• Secondary  Efficacy  Endpoint  2: change  in psychometric  HE score  (PHES)  from  pre-intervention  to 
end of study  follow -up (Week  26) 
o Null hypothesis : The change in psychometric HE score (PHES) from pre -intervention to  
the end of study  follow  up is equal  in the VE303/study  drug  and placebo/control  arms.  
o Alternative hypothesis : The change in psychometric HE score (PHES) from pre - 
intervention to the end of study follow up will be greater (and beneficial) in the  
VE303/study  drug  arm than  the placebo/control arm.  
 
• Secondary  Efficacy  Endpoint  3: Diversity  from  pre-intervention  to post -intervention  (Week  6) 
8.4.3  REPORTING  UNANTICIPATED  PROBLEMS  TO PARTICIPANTS  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
28  
  
o Hypothesis: The administration of VE303 will be associated with a greater diversity in  
the microbiota (as assessed by metagenomics) between the two time points as  
compared  to placebo.  
 
  9.2 SAMPLE  SIZE  DETERMINATION   
Given  the short  duration  of follow -up (6 weeks)  until  the primary  safety  outcome, we  predict  <10%  
patient  drop  out. 
 
This is a small pilot  phase  2a study  focused  on safety  as the primary  outcome.  Given  2:1 randomization,  
12 patients  will receive  VE303. This  is similar  to other  safety  studies  in this population.(11, 12)  
 
  9.3 POPULATIONS  FOR ANALYSES   
We will analyze safety and efficacy data according to a modified Intention -to-Treat Analysis (i.e., all  
subjects  who  were  randomized  and received  at least  one dose  of VE303  or placebo).  
 
  9.4 STATISTICAL  ANALYSES   
 
In this small pilot  phase  2a study, the  focus  will be on evaluating  safety.  After  enrollment  of the first 9 
patients, we will perform interim analysis to evaluate safety of VE303 in this population. If there is no  
concern for a higher rate of SAEs in the VE303 group, enrollment will continue to reach a total of 18  
patients. Results from all 18 patients will be used together to evaluate safety and efficacy at trial  
completion.  
 
Demographic  characteristics  that are continuous  variables  with  a normal  distribution  will be reported  as 
a mean ± standard deviation. Continuous variables with a skewed distribution will be reported as  
median and interquartile range. Normality will be determined by the Shapiro -Wilk test. Demographic  
characteristics that are binary or categorical variables will be reported as a proportion in each category.  
If the continuous outcome is normally distributed, then we will perform a t -test and report the mean ±  
standard deviation as well as the confidence intervals. If the outcome is not normally distributed as  
determined by the Shapiro -Wilk test, we will perform a Wilcoxon Rank Sum test and report the median  
and interquartile  range.  
 
If the continuous  primary  outcome  is normally  distributed, then  we will perform  a t-test and report  the 
mean ± standard deviation as well as the confidence intervals. If the primary outcome is not normally  
distributed as determined by the Shapiro -Wilk test, we will perform a Wilcoxon Rank Sum test and  
report  the median  and interquartile  range.  
 
If the continuous secondary endpoint is normally distributed, then we will perform a t -test and report  
the mean ± standard deviation as well as the confidence intervals. If the secondary endpoint is not  
normally distributed as determined by the Shapiro -Wilk test, we will perform a Wilcoxon Rank Sum test  
and report the median and interquartile range. If the secondary endpoint is categorical, we will perform  
a Fisher’s  exact  test.  
9.4.1  GENERAL  APPROACH  
9.4.2  ANALYSIS  OF THE PRIMARY  EFFICACY  ENDPOINT(S)  
9.4.3  ANALYSIS  OF THE SECONDARY  ENDPOINT(S)  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
29  
  
 
We will compare  the rate of serious  adverse  events  per patient  between  the intervention  and control  
arms.  
 
Laboratory  data,  including  MELD  score,  if normally  distributed  will be tested  by t-test and reported  as 
mean ± standard deviation. If not normal, we will perform a Wilcoxon Rank Sum test and report the  
median  and interquartile  range.  
 
In this small population,  we will not compare  the overall incidence  of adverse  events  between  groups,  
but will report  these  descriptively.  We will report  the solicited  and unsolicited  AEs separately.  
 
Demographic  characteristics  that are continuous  variables  with  a normal  distribution  will be reported  as 
a mean ± standard deviation. Continuous variables with a skewed distribution will be reported as  
median and interquartile range. Normality will be determined by the Shapiro -Wilk test. Demographic  
characteristics  that are binary  or categorical  variables  will be reported  as a proportion  in each category.  
 
After the 9 th patient reaches Day 14 of the study , an interim analysis will be completed. Safety events 
will be evaluated at the interim analysis . If there are no concerning findings in the safety outcome, the 
study  will proceed  to a total  enrollment  of 18 subjects.  The interim  analysis  will be performed  by the 
DSMB  of 1 hepatologist, 1  infectious  disease  physician  and 1 statistician.  
 
The primary  analysis  will be stratified  by the presence  of TIPS.  No other  sub-group  analyses  are planned.  
 
Individual participant PHES scores, Stroop test scores, ammonia levels, and microbiome data will be  
listed  by time  point.  
 
Computational analyses will assess VE303 strain penetration in the recipient microbiome by comparing  
single -nucleotide  variants  in strain  level  data  between  the donor  and recipient,  with  the primary  
comparison being post -vancomycin/pre -VE303 (Day 1) compared to the final day of VE303 (Day 14). We  
will also calculate beta diversity between time points to assess change in microbial diversity before and  
after vancomycin, and over post -VE303 follow -up. We will examine taxa that differ significantly between  
pre- and post -VE303 administration,  and test the degree to which changes in cognitive outcomes are  
explained  by changes  in the abundance  of species  and functional pathways.  
 
  10    SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS   
 
  10.1  REGULATORY,  ETHICAL,  AND  STUDY  OVERSIGHT  CONSIDERATIONS   
 
9.4.4  SAFETY  ANALYSES  
9.4.5  BASELINE  DESCRIPTIVE  STATISTICS  
9.4.6  PLANNED  INTERIM  ANALYSES  
9.4.7  SUB -GROUP  ANALYSES  
9.4.8  TABULATION  OF INDIVIDUAL  PARTICIPANT  DATA  
9.4.9  EXPLORATORY  ANALYSES  
10.1.1  INFORMED  CONSENT  PROCESS  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
30  
  
 
Consent  forms  describing  in detail  the study  intervention,  study  procedures,  and risks  are given  to the 
participant  and written  documentation  of informed  consent  is required  prior  to starting  
intervention/administering  study  intervention.  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the  
study and continues throughout the individual’s study participation. Consent forms will be Institutional  
Review Board (IRB) -approved and the participant will be asked to read and review the document. The  
investigator will explain the research study to the participant and answer any questions that may arise.  
A verbal explanation will be provided in terms suited to the participant’s comprehension of the  
purposes,  procedures,  and potential  risks  of the study  and of their  rights  as research  participants.  
Participants will have the opportunity to carefully review the written consent form and ask questions  
prior to signing. The participants should have the opportunity to discuss the study with their family or  
surrogates or think about it prior to agreeing to participate. The participant will sign the informed  
consent document prior to any procedures being done specifically for the study. Participants must be  
informed that participation is voluntary and that they may withdraw from the study at any time, without  
prejudice.  A copy  of the informed  consent  document  will be  given  to the participants  for their  records.  
The informed  consent  process  will be  conducted  and documented  in the source  document  (including  the 
date), and the form signed, before the participant undergoes any study -specific procedures. The rights  
and welfare of the participants  will be protected  by emphasizing  to them that  the quality  of their  
medical  care  will not  be adversely  affected  if they  decline  to participate  in this study.  
 
A study  physician  investigator  will obtain  informed  consent. In  the case  that a patient  is in the medical  
practice of one of the investigators, the patient will have their information session and informed  
consent performed by another investigator. The consent form and protocol will be reviewed with the  
potential subject and any questions will be answered. Subjects will have the opportunity to take the  
consent  form  home  and have  2 weeks  to decide  if they  wish  to participate.  
 
Ability  to provide  informed  consent  will be determined  by study  investigator  assessment  of capacity  and 
a discussion with the subject’s primary hepatologist and, if needed, a mini -mental status exam. This  
study  is designed  to investigate  a novel  therapy  for patients  with  a history  of hepatic encephalopathy.  
Many patients with a history of hepatic encephalopathy have persistent cognitive deficits between overt  
episodes of encephalopathy. If ability to consent is in question, a mini -mental status exam will be  
performed. Subjects will require a score of 18 or greater in order to provide their own consent. A study  
physician investigator will review the consent form with each subject and perform a capacity  
assessment. Subjects will demonstrate capacity by being able to: 1) express an understanding of VE303  
and its risks and benefits, 2) express a choice about study participation, 3) describe how the study may  
have  an impact  on his or her life, 4) express  a comparison  between  choosing  to participate  and not. 
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable  
cause.  Written notification, documenting the reason for study suspension or termination, will be  
provided  by the suspending  or terminating  party  to study  participants,  investigator,  funding  agency,  the 
Investigational New Drug (IND) sponsor and regulatory authorities.  If the study is prematurely  
terminated  or suspended,  the Sponsor  Investigator  (SI) will promptly  inform  study  participants, the  
10.1.1.1  CONSENT/ASSENT  AND  OTHER  INFORMATIONAL  DOCUMENTS  PROVIDED  TO 
PARTICIPANTS  
10.1.1.2  CONSENT  PROCEDURES  AND  DOCUMENTATION  
10.1.2  STUDY  DISCONTINUATION  AND  CLOSURE  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
31  
  
Institutional  Review  Board  (IRB),  sponsor,  and FDA and will provide  the reason(s)  for the termination  or 
suspension.  Study participants will be contacted, as applicable, and be informed of changes to study  
visit schedule.  
 
Circumstances  that may  warrant  termination  or suspension  include, but  are not limited  to: 
• Determination  of unexpected,  significant,  or unacceptable  risk to participants  
• Demonstration  of efficacy  that would  warrant stopping  
• Insufficient  compliance  to protocol  requirements  
• Data  that are not sufficiently  complete  and/or  evaluable  
• Determination  that the primary  endpoint  has been  met 
• Determination  of futility  
 
Study  may  resume  once  concerns  about  safety,  protocol  compliance,  and data  quality  are addressed,  
and satisfy  the sponsor  investigator, IRB  and/or  Food  and Drug Administration  (FDA).  
 
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their  
staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of  
biological samples and genetic tests in addition to the clinical information relating to participants.  
Therefore, the study protocol, documentation, data, and all other information generated will be held in  
strict confidence. No information concerning the study or the data will be released to any unauthorized  
third  party  without  prior  written  approval of  the sponsor.  
 
All research  activities  will be conducted  in as private  a setting  as possible.  
 
The study monitor, representatives of the Institutional Review Board (IRB), regulatory agencies or  
pharmaceutical  company  supplying  study  product  may  inspect  all documents  and records  required  to be 
maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital)  
and pharmacy records for the participants in this study. The clinical study site will permit access to such  
records.  
 
The study participant’s contact information will be securely stored the University of Michigan during the  
study. At the end of the study, all records will continue to be kept in a secure location for as long a  
period  as dictated  by the reviewing  IRB, Institutional  policies, or  sponsor  investigator  requirements.  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will  
be transmitted  to and stored  on the University  of Michigan  server.  This will not include  the participant’s  
contact or identifying information. Rather, individual participants and their research data will be  
identified by a unique study identification number. The study data entry and study management  
systems used by research staff will be secured and password protected. At the end of the study, the  
data linking study identification number to participants identifying information will be destroyed. The  
deidentified  database  will be  archived  on the University  of Michigan  server.  
 
Data collected for this study will be analyzed and stored at the University of Michigan Gastroenterology  
and Hepatology  Division  and at Vedanta  Biosciences, Inc.,  and may  be used  academically  by the 
10.1.3  CONFIDENTIALITY  AND  PRIVACY  
10.1.4  FUTURE  USE  OF STORED  SPECIMENS  AND  DATA  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
32  
  
University  of Michigan  Gastroenterology  and Hepatology  Division  and commercially  by Vedanta  
Biosciences,  Inc. 
 
With the participant’s approval, de -identified biological samples will be stored in the University of  
Michigan Gastroenterology and Hepatology Division and at Vedanta Biosciences, Inc. These samples  
could  be used  academically  and commercially  for purposes  including,  but not limited  to, researching  the 
causes of liver disease, hepatic encephalopathy, and other conditions for which individuals with chronic  
liver  disease  are at increased  risk, and  to improve  treatment.  
 
During the conduct of the study, an individual participant can choose to withdraw consent to have  
biological specimens stored for future research. However, withdrawal of consent with regard to  
biosample storage may not be possible after the study is completed or after the samples have already  
been  analyzed.  
 
 
Sponsor  Investigator  
Patricia  Bloom  MD 
University  of Michigan  
Taubman Center, 1500 E. Medical  
Center  
978-460-0538  
ppbloom@umich.med.edu  
 
 
 
An independent  data  safety  monitoring  board  (DSMB)  comprised  of an independent  hepatologist,  
infectious  disease  physician, and  a statistician  will monitor  the study.  
 
In addition to formal monitoring visits by University of Michigan Institute of Clinical and Health Research  
(see  10.1.7),  Dr. Bloom  will be regularly  monitoring  the study  documents  and meeting  with  study  staff  to 
review the status of the study. Dr. Bloom will ultimately be responsible for protecting the rights, safety  
and welfare of all subjects enrolled in this study. In the case of Dr. Bloom’s absence, monitoring  
responsibilities  will be  delegated  to one of the study  sub-investigators  listed  in the IRB. 
 
 
To assure adequate protection of the rights of human subjects per 21 CFR part 312, this study will be  
monitored by the University of Michigan Institute of Clinical and Health Research (MICHR).  Routine  
monitoring will be scheduled at appropriate intervals, with more frequent visits occurring at the  
beginning  of the study.  A site  initiation  visit will take  place,  followed  by routine  monitoring  visits.  
Additional  visits  can be scheduled  at the request  of the  Sponsor -Investigator.  
 
The established  monitoring plan  will ensure  the quality  and integrity  of the data  throughout  the study  
conduct to verify adherence to the protocol, completeness and accuracy of study data and samples  
collected,  dispensing  and inventory  of the study  drug,  and compliance  with  regulations.  Monitoring  
10.1.5  KEY ROLES  AND  STUDY  GOVERNANCE  
10.1.6  SAFETY  OVERSIGHT  
10.1.7  CLINICAL  MONITORING  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
33  
  
visits  can be conducted  onsite  or remotely  with  appropriate  electronic  documentation  provided  to the 
study  monitors  for review.  
 
Blinded  aggregate  data  on safety  events  will be sent  from  the PI and study  staff  to co -investigators  and 
the DSMB.  
 
We will perform internal quality management of study conduct, data and biological specimen collection,  
documentation  and completion.  
 
Quality  control  (QC)  procedures  will be implemented  beginning  with  the data  entry  system  and data  QC 
checks that will be run on the database. Any missing data or data anomalies will be communicated to  
the PI, Dr. Bloom, for  clarification/resolution.  
 
Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial is  
conducted and data are generated and biological specimens are collected, documented (recorded), and  
reported in compliance with the protocol, International Conference on Harmonisation Good Clinical  
Practice  (ICH  GCP),  and applicable  regulatory  requirements  (e.g.,  Good  Laboratory  Practices  (GLP),  Good  
Manufacturing  Practices  (GMP)).  
 
The investigational  site will provide  direct  access  to all trial related  sites,  source  data/documents,  and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and  
regulatory  authorities.  
 
 
Data  collection  is the responsibility  of the clinical  trial staff  at the site under  the supervision  of the site 
investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and  
timeliness  of the data  reported.  
 
All source  documents  should  be completed  in a neat,  legible  manner  to ensure  accurate  interpretation  
of data.  
 
Hardcopies of the study visit worksheets will be provided for use as source document worksheets for  
recording data for each participant enrolled in the study.  Data recorded in the electronic case report  
form  (eCRF)  derived  from  source  documents  should  be consistent  with the  data recorded  on the  source  
documents.  
 
Clinical  data  (including  adverse  events  (AEs),  concomitant  medications,  and expected  adverse  reactions  
data) and clinical laboratory data will be entered into RedCap, a 21 CFR Part 11 -capable data capture  
system provided by the University of Michigan. The data system includes password protection and  
internal quality checks, such as automatic range checks, to identify data that appear inconsistent,  
incomplete,  or inaccurate.  Clinical  data  will be  entered  directly  from  the source  documents.  
 
10.1.8  QUALITY  ASSURANCE  AND  QUALITY  CONTROL  
10.1.9  DATA  HANDLING  AND  RECORD  KEEPING  
10.1.9.1  DATA  COLLECTION  AND  MANAGEMENT  RESPONSIBILITIES  
10.1.9.2  STUDY  RECORDS  RETENTION  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
34  
  
Study documents will be retained until at least 2 years have elapsed since the formal discontinuation of  
clinical  development  of the study  intervention.  These  documents  should  be retained  for a  longer  period,  
however, if required by local regulations. No records will be destroyed without the written consent of  
the sponsor  investigator, if  applicable.  
 
A protocol  deviation  is any noncompliance  with  the clinical  trial protocol  or International  Conference  on 
Harmonisation Good Clinical Practice (ICH GCP). The noncompliance may be either on the part of the  
participant,  the investigator,  or the study  site staff.  As a result  of deviations,  corrective  actions  are to be 
developed  by the site and implemented  promptly.  
 
These  practices  are consistent  with  ICH GCP:  
• 4.5 Compliance  with  Protocol,  sections  4.5.1,  4.5.2,  and 4.5.3  
• 5.1 Quality  Assurance  and Quality  Control,  section  5.1.1  
• 5.20  Noncompliance,  sections  5.20.1,  and 5.20.2.  
 
It is the responsibility of the investigator to use continuous vigilance to identify and report deviations  
within 7 working days of identification of the protocol deviation, or within 3 working days of the  
scheduled protocol -required activity.  Protocol deviations must be sent to the Institutional Review Board  
(IRB)  per their  policies.  
 
This study  will be  conducted  in accordance  with  the following  publication  and data  sharing  policies  and 
regulations:  
 
National  Institutes  of Health  (NIH)  Public  Access  Policy,  which  ensures  that the  public  has access  to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal  
manuscripts that arise from NIH funds to the digital archive PubMed Central  upon acceptance for  
publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded  
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As  
such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be  
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer - 
reviewed journals.  Data from this study may be requested from other researchers 2 years after the 
completion  of the study  by contacting Dr. Patricia  Bloom.  
 
The independence  of this study  from  any actual  or perceived  influence,  such  as by the pharmaceutical  
industry, is critical.  Therefore, any actual conflict of interest of persons who have a role in the design,  
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore,  
persons who have a perceived conflict of interest will be required to have such conflicts managed in a  
way that is appropriate  to their  participation  in the design  and conduct  of this trial.  
 
  10.2  ADDITIONAL  CONSIDERATIONS   
 
NA 
10.1.10  
 PROTOCOL  DEVIATIONS  
10.1.11  
 PUBLICATION  AND  DATA  SHARING  POLICY  
10.1.12  
 CONFLICT  OF INTEREST  POLICY  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
35  
  
  10.3  ABBREVIATIONS   
 
AE Adverse  Event  
CFR Code  of Federal Regulations  
CLIA  Clinical  Laboratory  Improvement  Amendments  
CMP  Clinical  Monitoring  Plan  
COC  Certificate  of Confidentiality  
CONSORT  Consolidated  Standards  of Reporting  Trials  
CRF Case  Report  Form  
DCC Data  Coordinating  Center  
DHHS  Department  of Health  and Human  Services  
DSMB  Data  Safety  Monitoring  Board  
DRE Disease -Related  Event  
EC Ethics  Committee  
eCRF  Electronic  Case  Report  Forms  
FDA Food  and Drug Administration  
FDAAA  Food  and Drug  Administration  Amendments  Act of 2007  
FFR Federal  Financial  Report  
GCP Good  Clinical  Practice  
GLP Good  Laboratory  Practices  
GMP  Good  Manufacturing  Practices  
GWAS  Genome -Wide  Association  Studies  
HE Hepatic  encephalopathy  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
IB Investigator’s  Brochure  
ICH International  Conference  on Harmonisation  
ICMJE  International  Committee  of Medical  Journal  Editors  
IND Investigational  New  Drug  Application  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
ISO International  Organization  for Standardization  
ITT Intention -To-Treat  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MSDS  Material  Safety  Data  Sheet  
NCT National  Clinical  Trial  
NIH National Institutes  of Health  
OHE  Overt  hepatic  encephalopathy  
OHRP  Office  for Human  Research  Protections  
PI Principal  Investigator  
QA Quality  Assurance  
QC Quality  Control  
SAE Serious  Adverse  Event  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
36  
  
SMC  Safety  Monitoring  Committee  
SOA  Schedule  of Activities  
SOC System  Organ  Class  
SOP Standard  Operating  Procedure  
UP Unanticipated  Problem  
US United  States  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
37  
  
  10.4  PROTOCOL  AMENDMENT  HISTORY   
The table below is intended to capture changes of IRB -approved versions of the protocol, including a  
description of the change and rationale. A Summary of Changes table for the current amendment is  
located  in the Protocol Title  Page.  
 
Version  Date  Description  of Change  Brief Rationale  
V2 3/15/2021  Addition of amylase and lipase  
monitoring.  
Enhanced creatinine monitoring with  
vancomycin.  
Addition  of solicited  AEs.  
Added  detail  to individual and  study - 
wide  halting  rules.   Response  to FDA request.  
V3 3/24/2021  Addition of the following exclusion  
criteria: any GI surgery in the last  
year  
Revision  of protocol  number  and 
addition  of IND number   Response  to FDA request.  
 
 Minor  editorial  changes  
V4 5/16/2021  Add exclusion  criteria  for oral 
contraceptive  pills  Response  to IRB 
 Minor  editorial  changes  
V4 6/10/2021  Add NCT number  Response  to clinicaltrial.gov team 
request . 
V5 4/1/2022  Fix discrepancy on page 16 and 27 of 
the protocol on when the interim 
analysis would occur.  
After the first 9 patients have 
completed treatment, an interim 
analysis will be completed.  Investigator initiated edits. 
Discrepancy identified by PI.  
V6 11/28/2022  Updated for recent VE303 IB update and 
also to plan for unblinding for end of study 
analyses  New VE303 IB.  
Planning for end of study analyses.  
    
    
    
    
    
    
    
    
    
    
 
 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
38  
  
  11   REFERENCES   
 
1. Vilstrup H; Amodio P; Bajaj J; Cordoba J; Ferenci P; Mullen KD, et al. Hepatic encephalopathy in chronic  
liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the  
European Association  for the Study  of the Liver.  Hepatology  (Baltimore,  Md).  2014;60(2):715 -35. 
2. Gluud  LL; Vilstrup  H; Morgan  MY. Nonabsorbable  disaccharides  for hepatic  encephalopathy:  A systematic  
review  and meta -analysis.  Hepatology  (Baltimore, Md).  2016;64(3):908 -22. 
3. Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB, et al. Rifaximin treatment in hepatic  
encephalopathy.  The New  England  journal  of medicine.  2010;362(12):1071 -81. 
4. Kappus MR; Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. Clinical  
gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological  
Association.  2012;10(11):1208 -19. 
5. Wijdicks  EF. Hepatic  Encephalopathy.  The New  England  journal of  medicine.  2016;375(17):1660 -70. 
6. Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA, et al. Effect of rifaximin on gut  
microbiota composition in advanced liver disease and its complications. World journal of gastroenterology.  
2015;21(43):12322 -33. 
7. Riggio O; Varriale M; Testore GP; Di Rosa R; Di Rosa E; Merli M, et al. Effect of lactitol and lactulose  
administration  on the fecal  flora  in cirrhotic  patients.  Journal  of clinical  gastroenterology.  1990;12(4):433 -6. 
8. Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT, et al. Modulation of the metabiome  
by rifaximin  in patients  with  cirrhosis  and minimal  hepatic  encephalopathy.  PloS one.  2013;8(4):e60042.  
9. Shen TC; Albenberg L; Bittinger K; Chehoud  C; Chen YY; Judge CA, et al. Engineering the gut microbiota to  
treat  hyperammonemia.  The Journal  of clinical  investigation.  2015;125(7):2841 -50. 
10. Dalal R; McGee RG; Riordan SM; Webster AC. Probiotics for people with hepatic encephalopathy. The  
Cochrane  database  of systematic  reviews.  2017;2:CD008716.  
11. Bajaj JS; Kassam Z; Fagan A; Gavis EA; Liu E; Cox IJ, et al. Fecal Microbiota Transplant from a Rational Stool  
Donor  Improves  Hepatic  Encephalopathy:  A Randomized  Clinical  Trial.  Hepatology  (Baltimore,  Md).  2017.  
12. Bajaj JS; Salzman NH; Acharya C; Sterling RK; White MB; Gavis EA, et al. Fecal Microbial Transplant  
Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo -Controlled Trial. Hepatology  
(Baltimore,  Md).  2019;70(5):1690 -703.  
13. Zhang Z; Zhai H; Geng J; Yu R; Ren H; Fan H, et al. Large -scale survey of gut microbiota associated with  
MHE  Via 16S rRNA -based  pyrosequencing.  The American  Journal  of Gastroenterology.  2013;108(10):1601 -11. 
14. Qin N; Yang F; Li A; Prifti E; Chen Y; Shao L, et al. Alterations of the human gut microbiome in liver  
cirrhosis.  Nature.  2014;513(7516):59 -64. 
15. Montoliu C; Piedrafita B; Serra MA; del Olmo JA; Urios  A; Rodrigo JM, et al. IL -6 and IL -18 in blood may  
discriminate cirrhotic patients with and without minimal hepatic encephalopathy. Journal of clinical  
gastroenterology.  2009;43(3):272 -9. 
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
39  
  
16. Luo M; Li L; Yang EN; Cao WK. Relationship between interleukin -6 and ammonia in patients with minimal  
hepatic encephalopathy due to liver cirrhosis. Hepatology research : the official journal of the Japan Society of  
Hepatology.  2012;42(12):1202 -10. 
17. Shawcross DL; Davies NA; Williams R; Jalan R. Systemic inflammatory response exacerbates the  
neuropsychological  effects  of induced  hyperammonemia  in cirrhosis.  Journal  of hepatology.  2004;40(2):247 -54. 
18. Odeh M; Sabo E; Srugo I; Oliven A. Relationship between tumor necrosis factor -alpha and ammonia in  
patients  with  hepatic  encephalopathy  due to chronic  liver  failure.  Annals  of Medicine.  2005;37(8):603 -12. 
19. Breyner NM; Michon  C; de Sousa CS; Vilas Boas PB; Chain F; Azevedo VA, et al. Microbial Anti - 
Inflammatory Molecule (MAM) from Faecalibacterium prausnitzii Shows a Protective Effect on DNBS and DSS - 
Induced  Colitis  Model  in Mice  through  Inhibition  of NF-kappaB  Pathway. Frontiers  in microbiology.  2017;8:114.  
20. Cao Y; Shen J; Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory  
Bowel Disease: A Meta -Analysis and Systematic Review of the Literature. Gastroenterology research and practice.  
2014;2014:872725.  
21. Martin R; Miquel S; Benevides L; Bridonneau C; Robert V; Hudault S, et al. Functional Characterization of  
Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F.  
prausnitzii  as a Next -Generation  Probiotic.  Frontiers  in microbiology.  2017;8:1226.  
22. Miquel S; Martin R; Rossi O; Bermudez -Humaran LG; Chatel JM; Sokol H, et al. Faecalibacterium prausnitzii  
and human  intestinal  health.  Current  opinion  in microbiology.  2013;16(3):255 -61. 
23. Usami  M; Miyoshi M; Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World journal of  
gastroenterology.  2015;21(41):11597 -608.  
24. Miyoshi M; Sakaki H; Usami M; Iizuka N; Shuno K; Aoyama M, et al. Oral administration of tributyrin  
increases concentration of butyrate in the portal vein and prevents lipopolysaccharide -induced liver injury in rats.  
Clinical  nutrition  (Edinburgh,  Scotland).  2011;30(2):252 -8. 
25. Atarashi K; Tanoue T; Oshima K; Suda W; Nagano Y; Nishikawa H, et al. Treg induction by a rationally  
selected  mixture  of Clostridia  strains  from  the human  microbiota.  Nature.  2013;500(7461):232 -6. 
26. Furusawa Y; Obata Y; Fukuda S; Endo TA; Nakato G; Takahashi D, et al. Commensal microbe -derived  
butyrate  induces  the differentiation  of colonic  regulatory  T cells.  Nature.  2013;504(7480):446 -50. 
27. Randolph C; Hilsabeck R; Kato A; Kharbanda P; Li YY; Mapelli D, et al. Neuropsychological assessment of  
hepatic encephalopathy: ISHEN practice guidelines. Liver international : official journal of the International  
Association  for the Study  of the Liver.  2009;29(5):629 -35. 
28. Pringle PL; Soto MT; Chung RT; Hohmann E. Patients With Cirrhosis Require More Fecal Microbiota  
Capsules  to Cure  Refractory  and Recurrent  Clostridium  difficile  Infections.  Clinical  gastroenterology  and hepatology  
: the official  clinical  practice  journal  of the American  Gastroenterological  Association.  2018.  
29. Bajaj JS; Thacker LR; Heuman  DM; Fuchs M; Sterling RK; Sanyal AJ, et al. The Stroop smartphone  
application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (Baltimore, Md).  
2013;58(3):1122 -32. 
30. Bajaj JS; Heuman DM; Sterling RK; Sanyal AJ; Siddiqui M; Matherly S, et al. Validation of EncephalApp,  
Smartphone -Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. Clinical gastroenterology and  
hepatology : the official clinical practice journal of the American Gastroenterological Association.  
2015;13(10):1828 -35.e1.  
VE303  to Treat  HE 
Protocol  number:  HUM00194437  Version  6 
14 November 2022  
40  
  
31. Allampati S; Duarte -Rojo A; Thacker LR; Patidar KR; White MB; Klair JS, et al. Diagnosis of Minimal Hepatic  
Encephalopathy Using Stroop EncephalApp: A Multicenter US -Based, Norm -Based Study. Am J Gastroenterol.  
2016;111(1):78 -86. 
 
 
CONTRACEPTIVESa ALLOWED  DURING  THE STUDY  INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of < 1% per year when used  
consistently  and correctly.  
• Implantable  progestogen -only  hormone  contraception  associated  with  inhibition  of ovulationc 
• Intrauterine  device  (IUD)  
• Intrauterine  hormone -releasing  system  (IUS)c 
• Bilateral  tubal  occlusion  
• Azoospermic partner  (vasectomized  or due to  a medical  cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner  
of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional  
highly effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participant can come from the site personnel’s review of  
the participant’s  medical  records,  medical  examination,  or medical  history  interview.  
Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used consistently and  
correctly.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual  
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual  
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual  
lifestyle  of the participant.  
a) Contraceptive use by men or women should be consistent with local regulations regarding the use of  
contraceptive  methods for  those  participating  in clinical  studies.  
b) Failure rate of < 1% per year when used consistently and correctly. Typical use failure rates differ from those  
when  used  consistently  and correctly.  
c) Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with  
Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which  
inhibit  ovulation  as the primary  mode  of action.  
Note: Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus),  
spermicides  only,  and lactational  amenorrhea  method  (LAM)  are not acceptable  methods  of contraception.  
Male  condom  and female  condom  should  not be used  together  (due  to risk of failure  from  friction).  
 
Table  obtained  from  the TransCelerate  Protocol  Library  
12   APPENDIX  1 